US.MRNA · Moderna

{
  "risk": {
    "level": "Elevated",
    "reason": "risk management score >= 5/10",
    "position": {
      "score": 1.1,
      "details": {
        "atrPct": 8.33361116899354,
        "turnoverUsdM": 2212.88728575,
        "liquidityPoints": 0.8,
        "volatilityPoints": 0.3
      }
    },
    "rrPoints": 1.4,
    "stopLevels": {
      "symbol": "US.MRNA",
      "rr_range": "1:1.0-1:2.5",
      "risk_profile": "中等",
      "stop_loss_price": 119.9742,
      "strength_details": {
        "ma_score": 1.5,
        "atr_score": 1,
        "rsi_score": 1,
        "macd_score": 1.5,
        "volume_score": 1
      },
      "market_adjustment": 1,
      "risk_reward_ratio": 1,
      "stop_loss_percent": 16.7,
      "take_profit_price": 159.6473,
      "target_multiplier": 1.6,
      "technical_strength": 1.22,
      "take_profit_percent": 10.9
    },
    "positionPoints": 1.1,
    "stopLossPoints": 0.6,
    "diversification": {
      "score": 2,
      "details": {
        "method": "sector concentration proxy; no portfolio holdings used",
        "sector": "Health Care",
        "concentratedSectorPenalty": 0
      }
    },
    "riskRewardRatio": 1.2,
    "stopLossPercent": 15,
    "diversificationPoints": 2
  },
  "total": {
    "max": 160,
    "result": 48.7,
    "formula": "score_with_momentum_v2 = main_score + momentum_5d_v2_score",
    "baseScore": 45.7,
    "modelVersion": "cursor_18_27_news_v2_160",
    "momentum5dScore": 3
  },
  "market": {
    "ma20": 133.404,
    "ma50": 91.0366,
    "close": 143.97,
    "prevClose": 136.62,
    "avgVolume20": 34205779,
    "volumeRatio": 0.45,
    "changePercent": 5.38
  },
  "sources": {
    "catalyst": "finnhub_news_keyword_model",
    "sentiment": "finnhub_news_keyword_model",
    "fundamentals": "fmp_stable",
    "institutional": null,
    "marketContext": "twelvedata+fred"
  },
  "barCount": 60,
  "momentum": {
    "max": 50,
    "result": 3,
    "details": {
      "ret_5d": -0.0329146234970108,
      "max_score": 50,
      "max_total": 50,
      "raw_total": 3,
      "vcp_bonus": 0,
      "vol_ratio": 0.45413993223271576,
      "ret_points": 0,
      "vol_points": 0,
      "range_ratio": 1.0810145353237584,
      "volat_points": 0,
      "day_range_pct": 0.1021039730499411,
      "model_version": "cursor_18_27_news_v2_160",
      "available_bars": 30,
      "breakout_points": 0,
      "partial_history": false,
      "pullback_points": 3,
      "breakout_vol_bonus": 0,
      "first_breakout_20d": false,
      "return_window_days": 5,
      "first_breakout_bonus": 0,
      "breakout_quality_points": 0
    },
    "formula": "Cursor_18.25 5D momentum v2 0-50",
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "scoreMax": 110,
  "composite": {
    "max": 160,
    "result": 48.7,
    "formula": "Cursor_18.25 ranking score v2 (score_with_momentum_v2)",
    "weights": [
      {
        "raw": 2.5,
        "label": "基本面",
        "weight": "5/110",
        "normalized": 50,
        "contribution": 2.5
      },
      {
        "raw": 10,
        "label": "資金流",
        "weight": "20/110",
        "normalized": 50,
        "contribution": 10
      },
      {
        "raw": 6.2,
        "label": "市場環境",
        "weight": "15/110",
        "normalized": 41.33,
        "contribution": 6.2
      },
      {
        "raw": 2,
        "label": "催化劑",
        "weight": "20/110",
        "normalized": 10,
        "contribution": 2
      },
      {
        "raw": 5.1,
        "label": "風險管理",
        "weight": "10/110",
        "normalized": 51,
        "contribution": 5.1
      },
      {
        "raw": 15.9,
        "label": "技術信號",
        "weight": "30/110",
        "normalized": 53,
        "contribution": 15.9
      },
      {
        "raw": 4,
        "label": "情緒分析",
        "weight": "10/110",
        "normalized": 40,
        "contribution": 4
      }
    ],
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "momentumMax": 50,
  "scoreStatus": "incomplete",
  "standard110": {
    "rating": "避免",
    "result": 45.7,
    "details": [
      "基本面分析總分: 2.5/5分",
      "資金流分析總分: 10/20分",
      "市場環境分析總分: 6.2/15分",
      "催化劑分析: 2/20分",
      "風險管理總分: 5.1/10分",
      "技術信號分析總分: 15.9/30分",
      "情緒分析: 4/10分",
      "共振率(僅顯示不加分): 0%"
    ],
    "formula": "基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10",
    "dimensionScores": {
      "催化劑": 2,
      "基本面": 2.5,
      "資金流": 10,
      "市場環境": 6.2,
      "情緒分析": 4,
      "技術信號": 15.9,
      "風險管理": 5.1
    },
    "dimensionDetails": {
      "催化劑": {
        "max": 20,
        "grade": "較差",
        "items": {
          "catalyst": {
            "score": 2,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "catalystCount": 0
            }
          },
          "catalystPoints": 2
        }
      },
      "基本面": {
        "max": 5,
        "grade": "較差",
        "items": {
          "pbPoints": 0.2,
          "pePoints": 0,
          "epsPoints": 0.75,
          "roePoints": 0,
          "debtPoints": 0.5,
          "marginPoints": 0,
          "turnoverUsdM": 2212.88728575,
          "volumePoints": 0.5,
          "revenuePoints": 0,
          "dividendPoints": 0,
          "marketCapPoints": 0.5
        },
        "source": "fmp_stable"
      },
      "資金流": {
        "max": 20,
        "grade": "較差",
        "items": {
          "cmfPoints": 3.2,
          "mfiPoints": 1.6,
          "obvPoints": 2.4,
          "vwapPoints": 0.8,
          "institutional": {
            "score": 2,
            "details": {
              "source": "optional-neutral",
              "warning": {
                "code": "INSTITUTIONAL_DATA_OPTIONAL",
                "symbol": "US.MRNA",
                "message": "Institutional ownership is unavailable; neutral 2/4 money-flow treatment used."
              },
              "optional": true,
              "holderCount": null,
              "holderPoints": 2,
              "top10ShareRatio": null,
              "concentrationPenalty": 0
            }
          },
          "institutionPoints": 2
        }
      },
      "市場環境": {
        "max": 15,
        "grade": "較差",
        "items": {
          "vix": {
            "score": 0,
            "details": {
              "source": "twelvedata+fred",
              "missing": true,
              "vixClose": null
            }
          },
          "trend": {
            "score": 2.8,
            "details": {
              "qqq": {
                "ma20": 715.6679992,
                "ma50": 710.4063990999997,
                "name": "QQQ",
                "close": 714.88,
                "points": 1.4
              },
              "spy": {
                "ma20": 766.87899445,
                "ma50": 758.61640102,
                "name": "SPY",
                "close": 764.28998,
                "points": 1.4
              },
              "source": "twelvedata+fred"
            }
          },
          "atrPct": 8.33361116899354,
          "atrPoints": 1,
          "cciPoints": 2.4,
          "vixPoints": 0,
          "marketTrendPoints": 2.8
        }
      },
      "情緒分析": {
        "max": 10,
        "grade": "較差",
        "items": {
          "sentiment": {
            "score": 4,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "negativeHits": 0,
              "positiveHits": 2,
              "sentimentScoreRaw": 0.6
            }
          },
          "sentimentData": {
            "raw": [
              {
                "id": 142060793,
                "url": "https://finnhub.io/api/news?id=501b1bfa2a396fea7bf6a4009d23874fce74b44d31e36558453bdad953889fd4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Manufacturing hurdles are just one challenge the industry must overcome to commercialize personalized mRNA cancer vaccines.",
                "category": "company",
                "datetime": 1789031853,
                "headline": "mRNA cancer vaccines’ biggest barriers to market"
              },
              {
                "id": 141950162,
                "url": "https://finnhub.io/api/news?id=70423431bc7b150e3630ade48f615f5dd07d0c36f4e85b7c28b19b44f9016e98",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna stock surges 143% in a month on positive cancer therapy results, but competition and valuation raise key questions for investors.",
                "category": "company",
                "datetime": 1788878400,
                "headline": "MRNA Stock Soars 143% in a Month: Time to Buy, Hold or Sell?"
              },
              {
                "id": 141593799,
                "url": "https://finnhub.io/api/news?id=cd0695ce2b9ce5137c70db7c038f204af76712c3926ff3c3aa50bec39f1a7103",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna shares have soared, sunk, and soared again. You might want to consider them.",
                "category": "company",
                "datetime": 1788696900,
                "headline": "If You'd Invested in Moderna (MRNA) Stock 5 Years Ago, Here's How Much You'd Have Today (Hint: You'd Be Disappointed -- But Not If You Bought It 1 Year Ago.)"
              },
              {
                "id": 141496428,
                "url": "https://finnhub.io/api/news?id=ea9d00dd409da726a7a80134861f63535b67a9a04acb46261c5da486c261a1fd",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna (NasdaqGS:MRNA) has started a Phase 3 trial of its mRNA based bird flu vaccine, moving the program into late stage testing. The trial is supported by a major international partnership focused on pandemic preparedness. Moderna has tied the program to commitments for equitable global access, including reserved manufacturing capacity for low and middle income countries. This push into mRNA vaccines for emerging infectious diseases points to a wider theme in healthcare that is worth...",
                "category": "company",
                "datetime": 1788581900,
                "headline": "What Does Moderna (MRNA) Bird Flu Phase 3 Trial Mean For Its Growth?"
              },
              {
                "id": 141482013,
                "url": "https://finnhub.io/api/news?id=16506b56cfda44cdf484710a665b2161e464aed9d16a70e18726ffc7a602d35a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna (MRNA) drew fresh attention after completing a US$2.6b zero coupon convertible notes offering due 2032 and separately announcing an additional US$2b 2032 convertible notes issue, both placed under Rule 144A. Moderna's recent completion of zero coupon notes and the additional 2032 convertible announcement come after a surge in momentum, with the share price delivering a 30 day return of 158.73% and a year to date share price return of 371.65%, while the 1 year total shareholder return...",
                "category": "company",
                "datetime": 1788567528,
                "headline": "Is Moderna (MRNA) Fully Valued After Its New 2032 Convertible Notes?"
              },
              {
                "id": 141461194,
                "url": "https://finnhub.io/api/news?id=e49f8e9394d1cc262489e45bc635aadf2df42360c50b0c3dc0db8d049daad597",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "The vaccine maker is making an increasingly robust case that it isn't just a pandemic stock.",
                "category": "company",
                "datetime": 1788556500,
                "headline": "Wall Street Has Cooled on Moderna After Its Stock Jumped Over 5X. But Does the mRNA Leader Have More Room to Run?"
              },
              {
                "id": 141464843,
                "url": "https://finnhub.io/api/news?id=f4e2fcaf4d0c4ace10aecbb0b4efeecfe2c603e22496cb237436bb34e441e932",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna stock has delivered a very large 1 year gain, yet the company still screens as expensive on broad valuation checks. After that kind of move, the question for investors is whether the current price already reflects much of the good news around the mRNA pipeline. The share price return over the past 12 months is above 500%, which sets a high bar for what future progress on products and earnings needs to justify. Recent approvals for updated COVID vaccines and the first mRNA flu shot,...",
                "category": "company",
                "datetime": 1788556108,
                "headline": "Moderna (MRNA) Stock Looks Expensive On Sales After A Very Large Run"
              },
              {
                "id": 141425864,
                "url": "https://finnhub.io/api/news?id=da4c67bc94969150666b5f601b1d7abff304311fb75f11c4b526f760cae1c708",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "GSK PLC's (LSE:GSK, NYSE:GSK) experimental mRNA flu vaccine produced data that closely resemble Moderna's own candidate, according to Deutsche Bank. Analyst Emmanuel Papadakis reviewed detailed phase II results GSK presented at the OPTIONS XIII Conference for the Control of Influenza last...",
                "category": "company",
                "datetime": 1788520200,
                "headline": "GSK's mRNA flu vaccine data closely tracks Moderna's, Deutsche Bank says"
              }
            ],
            "raw_source": [
              {
                "id": 142090778,
                "url": "https://finnhub.io/api/news?id=157e03c002f762a96ca5dea8f18b75d379e07046fde6fdd5b0c2608a0a30c250",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Dow Jones futures: Despite Friday's bounce, the stock market had a tough week amid $100 oil prices and surging Treasury yields. Apple, Moderna are buys.",
                "category": "company",
                "datetime": 1789159162,
                "headline": "Dow Jones Futures: $100 Oil, Surging Yields Pressure Stocks With Fed Rate Hike Seen. Apple Leads New Buys."
              },
              {
                "id": 142090954,
                "url": "https://finnhub.io/api/news?id=a7c7f97cb74eef9cec2199c92441b054fa5b74803a1ce3703f945d84b708a000",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna had too much volatility as a swing trade. But ARK Genomics Revolution ETF allowed us to manage risk better.",
                "category": "company",
                "datetime": 1789159071,
                "headline": "How Cathie Wood's Fund Gave Us A Back Door To Moderna's Breakthrough"
              },
              {
                "id": 142089165,
                "url": "https://finnhub.io/api/news?id=730ee985635cf2cb4174a462055018cf2fb3f8c1a7fa9df3fbe6e9889f37215f",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "MRNA",
                "summary": "Join us in exploring the top gainers and losers within the S&P500 index one hour before the close of the markets on Friday as we examine the latest happenings in today's session.",
                "category": "company",
                "datetime": 1789153501,
                "headline": "Top S&P500 movers in Friday's session"
              },
              {
                "id": 142087699,
                "url": "https://finnhub.io/api/news?id=d008f77c83c23655aa93afca754d58b5809bf8c51f25fceeb225e41d40e1da58",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "MRNA",
                "summary": "Get insights into the S&P500 index performance on Friday. Explore the top gainers and losers within the S&P500 index in today's session.",
                "category": "company",
                "datetime": 1789144501,
                "headline": "Stay informed with the top movers within the S&P500 index on Friday."
              },
              {
                "id": 142087444,
                "url": "https://finnhub.io/api/news?id=9c28e90ce88d4870a13d7df5c21ab3737a9c3b83bc9b726f65702c45b7892fde",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna just surged 8% on a morning when its closest cancer-vaccine peer barely budged and its own pipeline partner slipped into the red, and no announcement, trial readout, or analyst call explains why.",
                "category": "company",
                "datetime": 1789142190,
                "headline": "Moderna Rallies 8% on 2026 Melt-Up Momentum Even While BioNTech and Merck Stay Flat"
              },
              {
                "id": 142087261,
                "url": "https://finnhub.io/api/news?id=ec7aa3b0bcef577d0681a669c3d489679091aa4b8001aae4ac3f44ebbe1aee81",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Techne (TECH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",
                "category": "company",
                "datetime": 1789140605,
                "headline": "Why Is Techne (TECH) Down 0.1% Since Last Earnings Report?"
              },
              {
                "id": 142086767,
                "url": "https://finnhub.io/api/news?id=3c32426f315e24a6bab7654c2f83dce2c1098a01113fd03b0ef50975df2904da",
                "image": "https://cdn.benzinga.com/files/images/story/2026/09/11/Display-Of-Stock-Market-Quotes.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "U.S. stocks rose; Frequency Electronics surged 30.7% after beating Q1 estimates, while ACV Auctions jumped 44.3% on Copart’s acquisition deal.",
                "category": "company",
                "datetime": 1789123395,
                "headline": "Frequency Electronics, ACV Auctions, HP And Other Big Stocks Moving Higher On Friday"
              },
              {
                "id": 142087559,
                "url": "https://finnhub.io/api/news?id=096f9fb5e11585c4891fb481b7935b7615675089c0619c2eec382b3910cf138b",
                "image": "https://cdn.benzinga.com/files/images/story/2026/09/10/Buffett-Musk-Shutterstock.png?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "A congresswoman recently bought stocks connected to Warren Buffett and Elon Musk.",
                "category": "company",
                "datetime": 1789067034,
                "headline": "Congresswoman Bets on Elon Musk, Warren Buffett: Here’s the Latest Stock Transactions"
              },
              {
                "id": 142063354,
                "url": "https://finnhub.io/api/news?id=048a492322933b269d7e80caf13a16d0fcc27cc8948d27855f206759fbc84081",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Amgen trades at a fraction of Moderna's valuation, but one company is burning cash while the other generates billions, a critical divide for income-focused investors.",
                "category": "company",
                "datetime": 1789057284,
                "headline": "Amgen vs. Moderna: Which Healthcare Stock Is a Better Buy in 2026?"
              },
              {
                "id": 142060793,
                "url": "https://finnhub.io/api/news?id=501b1bfa2a396fea7bf6a4009d23874fce74b44d31e36558453bdad953889fd4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Manufacturing hurdles are just one challenge the industry must overcome to commercialize personalized mRNA cancer vaccines.",
                "category": "company",
                "datetime": 1789031853,
                "headline": "mRNA cancer vaccines’ biggest barriers to market"
              },
              {
                "id": 142048040,
                "url": "https://finnhub.io/api/news?id=52562ddf2a6c2687841344a20584b7dbbff017f24bdf5eb5c9ae273fdb14f613",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2221231962/image_2221231962.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "MRNA",
                "summary": "If AI and robotics suddenly feel like they are moving faster, August gave investors plenty of evidence that the pace really is accelerating.",
                "category": "company",
                "datetime": 1789012200,
                "headline": "AI And Robotics In 2026: 16 Recent Developments For Investors"
              },
              {
                "id": 142027374,
                "url": "https://finnhub.io/api/news?id=12100754ed60010152ce1bdcaf47d2b1cd8a00e57f908809b27ef97e797f0132",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "AbbVie (NYSE:ABBV) executives outlined growth plans across immunology, oncology and neuroscience at a Wells Fargo conference, emphasizing continued momentum for its SKYRIZI and RINVOQ franchises, a pipeline of combination therapies and an approach to business development focused on assets that fit i",
                "category": "company",
                "datetime": 1788969928,
                "headline": "AbbVie Highlights SKYRIZI, RINVOQ Growth and Pipeline Catalysts at Wells Fargo Conference"
              },
              {
                "id": 141991628,
                "url": "https://finnhub.io/api/news?id=b0c60380221bf68b6b62d8e0691fda4ba0456fc7e91bb5fbf67c3d0df07368f2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "178-Page Report Tracks Merck's Cidara Buyout and CD388's Phase 3 Launch as Roche, Moderna, and GSK Compete Beyond the Vaccine Status QuoDublin, Sept. 09, 2026 (GLOBE NEWSWIRE) -- The \"Influenza a Infections - Market Insight, Epidemiology, and Market Forecast - 2036\" has been added to ResearchAndMarkets.com's offering. A new \"Influenza A - Market Insights, Epidemiology, and Market Forecast - 2036\" report provides a comprehensive analysis of the Influenza A market across the United States, EU4 cou",
                "category": "company",
                "datetime": 1788941220,
                "headline": "Influenza A Market Insight, Epidemiology, and Market Forecast - 2036 Now Available — See Why a 70% Vaccine Failure Rate Is Fueling the Race for Next-Gen Flu Therapies"
              },
              {
                "id": 141962577,
                "url": "https://finnhub.io/api/news?id=b3fa24628d8b85adc54ce55ff5a908ddb804fb3b6784003aac2b8d59a31fddca",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2226147604/image_2226147604.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "MRNA",
                "summary": "U.S. equity markets were mostly mixed this week, with modest gains in the major benchmarks masking weakness across several sectors.",
                "category": "company",
                "datetime": 1788911100,
                "headline": "ValuEngine Weekly Commentary: Advancing Nuclear Energy And Evaluating Its Current Place Within Dynamic Asset Strategies"
              },
              {
                "id": 141955220,
                "url": "https://finnhub.io/api/news?id=2229f093b5e5655f568374287a384e1e851efa215c037987aa01cbf40fb46ae9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Could cancer vaccines and AI drive the next wave of healthcare innovation?",
                "category": "company",
                "datetime": 1788900600,
                "headline": "AI, Cancer Vaccines, and Next-Gen Medicine"
              },
              {
                "id": 141950162,
                "url": "https://finnhub.io/api/news?id=70423431bc7b150e3630ade48f615f5dd07d0c36f4e85b7c28b19b44f9016e98",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna stock surges 143% in a month on positive cancer therapy results, but competition and valuation raise key questions for investors.",
                "category": "company",
                "datetime": 1788878400,
                "headline": "MRNA Stock Soars 143% in a Month: Time to Buy, Hold or Sell?"
              },
              {
                "id": 141950477,
                "url": "https://finnhub.io/api/news?id=5f463d79ff55c9a088f9414ade98ab89f3cbe7d318f874fc22a88f72fe6a248a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Data centers face drama as public pushback against the AI build-out is at a high.",
                "category": "company",
                "datetime": 1788873602,
                "headline": "Cancer Vaccines & Data Center Drama"
              },
              {
                "id": 141950156,
                "url": "https://finnhub.io/api/news?id=42df889edd57ef233368d6f8698eadbc5aa569a477a9fd479aacbb24ee6aec58",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "MRK trades near its 52-week high as Keytruda drives growth, while its pipeline and new products offer a path beyond the 2028 patent cliff.",
                "category": "company",
                "datetime": 1788871080,
                "headline": "Merck Trading Near 52-Week High: Is the Stock a Buy, Hold or Sell?"
              },
              {
                "id": 141950884,
                "url": "https://finnhub.io/api/news?id=7dde1935ca4db3895c170858d8580a7c3493bcfbedcbf60135ea8a3ecf36679e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna's stock is up over 100%.",
                "category": "company",
                "datetime": 1788869101,
                "headline": "Behind the Most Exciting Stock Pop in Years"
              },
              {
                "id": 141787034,
                "url": "https://finnhub.io/api/news?id=28056929daf7e863fdaa2b0207034941eafc3b574c601e0a07547ac1dadb006a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Personalized cancer vaccines are creating a diagnostics investment opportunity beyond Moderna and Merck, with tumor sequencing at its center.",
                "category": "company",
                "datetime": 1788832154,
                "headline": "The Cure for Cancer is Becoming an Investable Opportunity: Analyst Sees $600 Million for Tempus AI"
              },
              {
                "id": 141769189,
                "url": "https://finnhub.io/api/news?id=211bd61ff669f73275eceb475c405914f4b7b2507ee8b13cd834a3355d30e241",
                "image": "https://cdn.benzinga.com/files/images/story/2025/11/06/aggregated_options_2.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "This whale alert can help traders discover the next big trading opportunities.\nWhales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.\nTraders often",
                "category": "company",
                "datetime": 1788788115,
                "headline": "8 Health Care Stocks Whale Activity In Today’s Session"
              },
              {
                "id": 141760935,
                "url": "https://finnhub.io/api/news?id=9f51313c5b3c77384d06c621b598127ced700b1ca8ebed5cb5ba133ec949c83a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Dublin, Sept. 07, 2026 (GLOBE NEWSWIRE) -- The \"Vaccines Market Distribution by Type of Vaccine API, Targeted Patient Population, Type of Vaccines, Route of Administration, and Key Geographical Region - Trends and Forecasts Till 2035\" has been added to ResearchAndMarkets.com's offering. The global vaccines market is projected to increase from approximately USD 48 billion to USD 94 billion by 2030, representing a compound annual growth rate of about 11.9% during the forecast period. Market expans",
                "category": "company",
                "datetime": 1788778920,
                "headline": "Vaccines Global Market Intelligence Report 2026-2035 Featuring Bio Farma, Emergent BioSolutions, GC Pharma, GlaxoSmithKline, Janssen, Merck, Novavax, Moderna, Pfizer, Sanofi Pasteur, and Valneva"
              },
              {
                "id": 141771992,
                "url": "https://finnhub.io/api/news?id=65930b7b853fd9f7f55b76b0d4e7c6bd0e15781db8182a6c2e2b223d8e8c0694",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna has outpaced the healthcare sector, yet analysts remain skeptical about the stock’s outlook.",
                "category": "company",
                "datetime": 1788775988,
                "headline": "How Is Moderna's Stock Performance Compared to Other Healthcare Stocks"
              },
              {
                "id": 141762536,
                "url": "https://finnhub.io/api/news?id=755171ce4130cab475d6d9e4eb412f6569c568e60203dffab6ff579c86acade5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna, Pharvaris and AbbVie span short, mid and long-term healthcare setups, from melanoma data to a Phase 3 catalyst and 13 straight years of dividend hikes.",
                "category": "company",
                "datetime": 1788702600,
                "headline": "Moderna Just Doubled Overnight, and 2 More Healthcare Stocks Could Follow It"
              },
              {
                "id": 141593799,
                "url": "https://finnhub.io/api/news?id=cd0695ce2b9ce5137c70db7c038f204af76712c3926ff3c3aa50bec39f1a7103",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna shares have soared, sunk, and soared again. You might want to consider them.",
                "category": "company",
                "datetime": 1788696900,
                "headline": "If You'd Invested in Moderna (MRNA) Stock 5 Years Ago, Here's How Much You'd Have Today (Hint: You'd Be Disappointed -- But Not If You Bought It 1 Year Ago.)"
              },
              {
                "id": 141574521,
                "url": "https://finnhub.io/api/news?id=696a0087be65b16b185540e6c7c0ed466c123a717e884c14d7461d4872a414ff",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2290040711/image_2290040711.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "MRNA",
                "summary": "Since the close on the Thursday before Memorial Day, the S&P 500 has rallied 3.7%. Read more here.",
                "category": "company",
                "datetime": 1788661800,
                "headline": "Summer Flings And Heartbreaks"
              },
              {
                "id": 141496428,
                "url": "https://finnhub.io/api/news?id=ea9d00dd409da726a7a80134861f63535b67a9a04acb46261c5da486c261a1fd",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna (NasdaqGS:MRNA) has started a Phase 3 trial of its mRNA based bird flu vaccine, moving the program into late stage testing. The trial is supported by a major international partnership focused on pandemic preparedness. Moderna has tied the program to commitments for equitable global access, including reserved manufacturing capacity for low and middle income countries. This push into mRNA vaccines for emerging infectious diseases points to a wider theme in healthcare that is worth...",
                "category": "company",
                "datetime": 1788581900,
                "headline": "What Does Moderna (MRNA) Bird Flu Phase 3 Trial Mean For Its Growth?"
              },
              {
                "id": 141482013,
                "url": "https://finnhub.io/api/news?id=16506b56cfda44cdf484710a665b2161e464aed9d16a70e18726ffc7a602d35a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna (MRNA) drew fresh attention after completing a US$2.6b zero coupon convertible notes offering due 2032 and separately announcing an additional US$2b 2032 convertible notes issue, both placed under Rule 144A. Moderna's recent completion of zero coupon notes and the additional 2032 convertible announcement come after a surge in momentum, with the share price delivering a 30 day return of 158.73% and a year to date share price return of 371.65%, while the 1 year total shareholder return...",
                "category": "company",
                "datetime": 1788567528,
                "headline": "Is Moderna (MRNA) Fully Valued After Its New 2032 Convertible Notes?"
              },
              {
                "id": 141461194,
                "url": "https://finnhub.io/api/news?id=e49f8e9394d1cc262489e45bc635aadf2df42360c50b0c3dc0db8d049daad597",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "The vaccine maker is making an increasingly robust case that it isn't just a pandemic stock.",
                "category": "company",
                "datetime": 1788556500,
                "headline": "Wall Street Has Cooled on Moderna After Its Stock Jumped Over 5X. But Does the mRNA Leader Have More Room to Run?"
              },
              {
                "id": 141464843,
                "url": "https://finnhub.io/api/news?id=f4e2fcaf4d0c4ace10aecbb0b4efeecfe2c603e22496cb237436bb34e441e932",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna stock has delivered a very large 1 year gain, yet the company still screens as expensive on broad valuation checks. After that kind of move, the question for investors is whether the current price already reflects much of the good news around the mRNA pipeline. The share price return over the past 12 months is above 500%, which sets a high bar for what future progress on products and earnings needs to justify. Recent approvals for updated COVID vaccines and the first mRNA flu shot,...",
                "category": "company",
                "datetime": 1788556108,
                "headline": "Moderna (MRNA) Stock Looks Expensive On Sales After A Very Large Run"
              },
              {
                "id": 141437923,
                "url": "https://finnhub.io/api/news?id=b11c54b8856ccd4571ac290c9dbaaef79a28c5ec845b18426f1918e88d9b3249",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Recursion Pharmaceuticals (RXRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",
                "category": "company",
                "datetime": 1788535818,
                "headline": "Why Is Recursion Pharmaceuticals (RXRX) Up 8.2% Since Last Earnings Report?"
              },
              {
                "id": 141425030,
                "url": "https://finnhub.io/api/news?id=5030d26aa984c830818eda1c4b16e236d371557cd7f2407be913a5da2bf31ceb",
                "image": "https://www.chartmill.com/images/uploads/CM_Premarket_Movers_Small_free_90289f6b81.webp",
                "source": "ChartMill",
                "related": "MRNA",
                "summary": "Wondering what's happening in today's pre-market session? Stay tuned for the latest updates on S&P500 stock movements.",
                "category": "company",
                "datetime": 1788525301,
                "headline": "Stay updated with the S&P500 stocks that are on the move in today's pre-market session."
              },
              {
                "id": 141425864,
                "url": "https://finnhub.io/api/news?id=da4c67bc94969150666b5f601b1d7abff304311fb75f11c4b526f760cae1c708",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "GSK PLC's (LSE:GSK, NYSE:GSK) experimental mRNA flu vaccine produced data that closely resemble Moderna's own candidate, according to Deutsche Bank. Analyst Emmanuel Papadakis reviewed detailed phase II results GSK presented at the OPTIONS XIII Conference for the Control of Influenza last...",
                "category": "company",
                "datetime": 1788520200,
                "headline": "GSK's mRNA flu vaccine data closely tracks Moderna's, Deutsche Bank says"
              },
              {
                "id": 141425868,
                "url": "https://finnhub.io/api/news?id=c3a5152a36bbc7e9c08b11c0f72799b8f19c551f5eaeeb5e7cbc7fc1fa008118",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "The stocks featured in this article are seeing some big returns. Over the past month, they’ve outpaced the market due to some combination of positive news, upbeat results, or supportive macro developments. As such, investors are taking notice and bidding up shares.",
                "category": "company",
                "datetime": 1788518530,
                "headline": "3 Inflated  Stocks with Open Questions"
              },
              {
                "id": 141406941,
                "url": "https://finnhub.io/api/news?id=e5c46c66ef86dd37431efec175b6c67456f4a68507baec9a1e490ffa21c8b042",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Shares of biotechnology company Moderna (NASDAQ:MRNA) fell 2.9% in the afternoon session after Rothschild & Co Redburn analyst Simon Baker downgraded the company to Sell from Neutral on valuation concerns. Baker raised Moderna's price target to $81 from $40, representing a 46% downside from the previous day’s close of $150.81, CNBC reported.",
                "category": "company",
                "datetime": 1788485718,
                "headline": "Why Moderna (MRNA) Stock Is Down Today"
              },
              {
                "id": 141405194,
                "url": "https://finnhub.io/api/news?id=983d26415e41bc791b04d725868b5466a35d03b2fd4a91f0282aba978231dcef",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Both have attracted considerable attention from Wall Street recently.",
                "category": "company",
                "datetime": 1788472200,
                "headline": "BioNTech vs. Moderna: Which Is the Better Cancer Vaccine Stock to Buy Now?"
              },
              {
                "id": 141403523,
                "url": "https://finnhub.io/api/news?id=1bb1adddd9848981c1ec4238462275e64b89e0340003f691f5242cca88dfc968",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "MRNA",
                "summary": "Stay updated with the movement of S&P500 stocks in today's session. Discover which S&P500 stocks are making waves on Thursday.",
                "category": "company",
                "datetime": 1788462301,
                "headline": "Thursday's session: top gainers and losers in the S&P500 index"
              },
              {
                "id": 141403790,
                "url": "https://finnhub.io/api/news?id=1548687fecf537e8e4484d6edea21ed97a99feddaf4fd5587f4cad353faadd83",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Drugmakers are getting a boost from strong earnings and M&A. But they’re also havens in a rocky market.",
                "category": "company",
                "datetime": 1788457140,
                "headline": "Healthcare Stocks Pick Up Steam as Investors Play Offense and Defense"
              },
              {
                "id": 141401625,
                "url": "https://finnhub.io/api/news?id=7f9aedd8a41fb14ffcc587468eac74b7ff6e8786ce888f5fb9c434afbabf0e5f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "MRNA's newly approved mFlusiva faces a potential challenge as GSK advances an mRNA flu vaccine targeting two viral proteins.",
                "category": "company",
                "datetime": 1788456240,
                "headline": "Does Moderna's mRNA Flu Shot Face a New Challenge From GSK?"
              },
              {
                "id": 141401282,
                "url": "https://finnhub.io/api/news?id=844dd45cdb24402fd7cb0469555803baeb4b18d6993dc5e7f81d631a9138c782",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "MRNA",
                "summary": "Curious about the top performers within the S&P500 index in the middle of the day on Thursday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.",
                "category": "company",
                "datetime": 1788453301,
                "headline": "These S&P500 stocks are moving in today's session"
              },
              {
                "id": 141400381,
                "url": "https://finnhub.io/api/news?id=adeb5e4b160bfa4c1f7b5e497c2d42856d151be4b132e391f5aa87e4415edece",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Rothschild analyst Simon Baker downgrades Moderna stock to Sell from Neutral while doubling his price target.",
                "category": "company",
                "datetime": 1788448560,
                "headline": "Moderna’s Cancer Vaccine Rally Sparks Rare Sell Rating and Projected 45% Stock Drop"
              },
              {
                "id": 141400575,
                "url": "https://finnhub.io/api/news?id=8f04728f8e27b27d8d7027e2c131e79e5a16d3905def8f14329bc19d388181f9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Bamco, the advisory arm of Ron Baron’s Baron Capital Group, opened a new position in Moderna (NASDAQ:MRNA) during the second quarter of 2026. The fund bought about 2 million shares of the firm in the June quarter. The timing worked out. In August, Moderna shares nearly tripled on a positive Phase 3 report. Bamco also […]",
                "category": "company",
                "datetime": 1788446692,
                "headline": "This Fund Bought Moderna Before It Nearly Tripled. See Its 2 New Stock Picks"
              },
              {
                "id": 141403192,
                "url": "https://finnhub.io/api/news?id=222861cbe182e09bd124e5448a1086f89de7650eb4bc2e208436fb5e5363a845",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2193840462/image_2193840462.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "MRNA",
                "summary": "As legacy pharmaceutical models face structural challenges, targeting the underlying technology enablers of next-generation care offers a compelling approach for healthcare investors.",
                "category": "company",
                "datetime": 1788444600,
                "headline": "Why Moderna's Cancer Vaccine Matters To Investors"
              },
              {
                "id": 141399066,
                "url": "https://finnhub.io/api/news?id=4ed8f6ae48feabcf393751419af7282790ba8eb20c99c119c963c3abc6ab6946",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Broadcom upgraded, Ultragenyx downgraded: Wall Street's top analyst calls",
                "category": "company",
                "datetime": 1788442317,
                "headline": "Broadcom upgraded, Ultragenyx downgraded: Wall Street's top analyst calls"
              },
              {
                "id": 141397922,
                "url": "https://finnhub.io/api/news?id=73fa98e06527503066cea8ed06de0e1adee97cbfa1f61ab221ce2598fe4039a5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Markets wobble heading into the Labor Day weekend as bond vigilantes push back against Washington, oil stays tense with Middle East strikes escalating, and Wall Street analysts make bold calls on names ranging from Broadcom to Moderna that could reshape your portfolio positioning.",
                "category": "company",
                "datetime": 1788440746,
                "headline": "Here Are Thursday’s Top Wall Street Analyst Research Calls: Broadcom, Deere & Company, Dell Technologies, Devon Energy, Moderna, Permian Resources, PG&E, Thermo Fisher, Viper Energy, and More"
              },
              {
                "id": 141397712,
                "url": "https://finnhub.io/api/news?id=2dd7d4483cd4f670e119da44d572bf1091418e7f41588bec2d25cfe69ad8e822",
                "image": "https://www.chartmill.com/images/uploads/CM_Premarket_Movers_Small_free_90289f6b81.webp",
                "source": "ChartMill",
                "related": "MRNA",
                "summary": "The US market is yet to commence its session on Thursday, but let's get a preview of the pre-market session and explore the top S&P500 gainers and losers driving the early market movements.",
                "category": "company",
                "datetime": 1788438902,
                "headline": "These S&P500 stocks are moving in today's pre-market session"
              },
              {
                "id": 141402986,
                "url": "https://finnhub.io/api/news?id=5003a626c156989cd6fb2535b9c7efe2be9a6fdecb84031cd0e48590c56ad54b",
                "image": "https://cdn.benzinga.com/files/images/story/2026/09/03/Analysts-Adjust-Progressive-Targets.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "Analysts downgraded Ultragenyx, Moderna and Sonoco; targets fell for RARE and SON but rose for MRNA.",
                "category": "company",
                "datetime": 1788424853,
                "headline": "This Sonoco Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Thursday"
              },
              {
                "id": 141401171,
                "url": "https://finnhub.io/api/news?id=a36c710f22f5f49e8b98176b04c5d33ed18a41eab9209cd631020c646ee5eb80",
                "image": "https://cdn.benzinga.com/files/images/story/2026/09/03/Crowdstrike-Sign-And-Logo-At-Headquarter.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "Analysts revised price targets for Ultragenyx, UiPath, Netskope, Snowflake, Magnite, Broadcom, CrowdStrike and Moderna; ratings largely maintained.",
                "category": "company",
                "datetime": 1788424552,
                "headline": "CrowdStrike To Rally Over 15%? Here Are 10 Top Analyst Forecasts For Thursday"
              },
              {
                "id": 141403352,
                "url": "https://finnhub.io/api/news?id=0433e013fcd98bf2a9617ef186985a40834574f832ac7fbbf700d81fbb5a2cdd",
                "image": "",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "Rothschild & Co  analyst Simon Baker   downgrades Moderna (NASDAQ:MRNA) from Neutral to Sell and raises the price target from $40 to $81.",
                "category": "company",
                "datetime": 1788421882,
                "headline": "Rothschild & Co Downgrades Moderna to Sell, Raises Price Target to $81"
              },
              {
                "id": 141396877,
                "url": "https://finnhub.io/api/news?id=c79fadb8c7424c24b8db9fce5e390a61f7312a0a55cc2ab006bd9eb2cb5a23c4",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2286477227/image_2286477227.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "MRNA",
                "summary": "Moderna's upside hinges on Intismeran’s ability to scale across multiple tumor types, not just melanoma. Learn why MRNA stock is a strong buy.",
                "category": "company",
                "datetime": 1788417365,
                "headline": "Moderna: Massive Asymmetry About What The mRNA Is!"
              },
              {
                "id": 141386575,
                "url": "https://finnhub.io/api/news?id=f10db8c11f1ef95923f0496692010a7cf7263ceffcda10ee2c09224a2d2265b2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "During the August 31 episode of Mad Money, Jim Cramer addressed shifting market dynamics, highlighting how the fallout from heavily crowded hedge fund positions was finally unwinding. Turning his attention to a heavily shorted stock on Wall Street, Cramer pointed to Moderna, Inc. (NASDAQ:MRNA) and explained why skeptics were forced to rethink their thesis. He […]",
                "category": "company",
                "datetime": 1788385407,
                "headline": "Jim Cramer Explains Why Heavily Shorted Moderna (MRNA) Has Room to Run"
              },
              {
                "id": 141379809,
                "url": "https://finnhub.io/api/news?id=27c627420a301c328f07aa2ff7213289779a4ca998e46ffad2d56f041f875d36",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Alteogen's platform can turn intravenous biologics into injections, but payments depend on multiple products reaching milestones.",
                "category": "company",
                "datetime": 1788368568,
                "headline": "Novartis Rises as $3.22 Billion Deal Targets Faster Drug Delivery"
              },
              {
                "id": 141379734,
                "url": "https://finnhub.io/api/news?id=a034ee7c5d4c02063349fe11edb654779f3be525a8c9ca656e31aedd0a6bd4ab",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "TG4050 as a single agent has the potential to prevent recurrence in head and neck cancer Peer-reviewed publication in Nature Communications highlights the Phase 1 clinical and translational findings, including durable neoantigen-specific T cell responses Together, the long-term clinical and translational data further strengthen confidence in Transgene’s individualized neoantigen therapeutic vaccine approach and myvac® platform Strasbourg, France & Tokyo, Japan, September 2, 2026, 6:00 p.m. CET –",
                "category": "company",
                "datetime": 1788368400,
                "headline": "Transgene and Nec Report 100% Three-Year Disease-Free Survival with TG4050 and Publish Phase 1 Results in Nature Communications"
              },
              {
                "id": 141379813,
                "url": "https://finnhub.io/api/news?id=83de2d5643670260634bd9f38ff7a0c2c68e0ee39746f5f03d61f32ae1dc82cb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Alumis' (ALMS) share price drop after the disappointing results of a phase 2b trial of envudeucitini",
                "category": "company",
                "datetime": 1788367237,
                "headline": "Alumis' Share Price Fall After Envudeucitinib Trial Data Likely Overreaction, Oppenheimer Says"
              },
              {
                "id": 141378555,
                "url": "https://finnhub.io/api/news?id=72b263763da10ef17686651fa4d655f42b86aedcfc2d94987e8894902914a6b6",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "MRNA",
                "summary": "Stay informed about the performance of the S&P500 index in the middle of the day on Wednesday. Uncover the top gainers and losers in today's session for valuable insights.",
                "category": "company",
                "datetime": 1788366901,
                "headline": "Stay informed with the top movers within the S&P500 index on Wednesday."
              },
              {
                "id": 141379819,
                "url": "https://finnhub.io/api/news?id=a64fdd4280f1952b130f8c25d1558be0be050e099e1a656cc74a708d86298213",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Vertex (VRTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",
                "category": "company",
                "datetime": 1788366612,
                "headline": "Why Is Vertex (VRTX) Up 14.4% Since Last Earnings Report?"
              },
              {
                "id": 141379821,
                "url": "https://finnhub.io/api/news?id=05be3e1dbb863ad106435889fa84b14e5afd6eb53b86efc7aab48297653ce1d5",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Krystal Biotech (KRYS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",
                "category": "company",
                "datetime": 1788366608,
                "headline": "Krystal Biotech (KRYS) Up 12% Since Last Earnings Report: Can It Continue?"
              },
              {
                "id": 141379820,
                "url": "https://finnhub.io/api/news?id=8fa0ac4ea79a3ab4284357ac2c0792a7e90742679a51f5d9a0dfc17dbee46488",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Keros Therapeutics (KROS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",
                "category": "company",
                "datetime": 1788366608,
                "headline": "Why Is Keros Therapeutics (KROS) Up 8% Since Last Earnings Report?"
              },
              {
                "id": 141380065,
                "url": "https://finnhub.io/api/news?id=379246e2c6e287584c1be1be4a018cd7b81d27dcd1cd6fdfcbd364de31668d90",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Indivior Pharmaceuticals Inc. (INDV) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",
                "category": "company",
                "datetime": 1788366607,
                "headline": "Indivior Pharmaceuticals Inc. (INDV) Down 5.3% Since Last Earnings Report: Can It Rebound?"
              },
              {
                "id": 141379858,
                "url": "https://finnhub.io/api/news?id=4b776804384ccdc1fc9c4d0bd1c18c9b9b83fbb7d46444f8c9e4066c88a2c2e8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",
                "category": "company",
                "datetime": 1788366607,
                "headline": "Why Is Jazz (JAZZ) Down 6.9% Since Last Earnings Report?"
              },
              {
                "id": 141379714,
                "url": "https://finnhub.io/api/news?id=d961378e58675e5c52ee90553ab694c6aee0cf1040150d8b9e000742c4ca5c9f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "CRISPR Therapeutics (CRSP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",
                "category": "company",
                "datetime": 1788366605,
                "headline": "Why Is CRISPR Therapeutics (CRSP) Up 7.1% Since Last Earnings Report?"
              },
              {
                "id": 141379507,
                "url": "https://finnhub.io/api/news?id=6aeaab990e198b9987c02de29db461782a6eaf30fae7daa0c0b3801671b67d89",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "European equities traded in the US as American depositary receipts were trending higher late Wednesd",
                "category": "company",
                "datetime": 1788365622,
                "headline": "European Equities Traded in the US as American Depositary Receipts Track Higher in Wednesday Trading"
              },
              {
                "id": 141379859,
                "url": "https://finnhub.io/api/news?id=93ce5900c3fa1681c3c71ae1432698f1c995279031e7f4ebc38028cc2a640ca3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "GSK to advance its mRNA flu vaccine into phase III after phase II study has shown stronger immune responses and good tolerability.",
                "category": "company",
                "datetime": 1788365460,
                "headline": "GSK to Advance mRNA Influenza Vaccine Into Phase III Development"
              },
              {
                "id": 141380069,
                "url": "https://finnhub.io/api/news?id=d3e93bf7965640f1680c512829c20b42b98ac554ac2e3478028eb24a9a72a794",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Purple Biotech (NASDAQ:PPBT) has received a U. S.",
                "category": "company",
                "datetime": 1788365252,
                "headline": "Purple Biotech U.S. Patent Allowance Strengthens CAPTN-3 Multispecific Antibody Protection"
              },
              {
                "id": 141380070,
                "url": "https://finnhub.io/api/news?id=a6d429c8e4fc6e93eec90f198cbd5ec9a427b91907233887b9d44bece69097ce",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Company announcement No. 45 / 2026 Correction: Zealand Pharma - Transactions related to share buy-back program (week 35, 2026) Copenhagen, Denmark, September 2, 2026 – Zealand Pharma A/S (\"the Company\" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, hereby corrects information regarding the dates for the reported transactions related to its share buy-back program (the \"Program\") for week 35 (August 24 – August 28, 2026)",
                "category": "company",
                "datetime": 1788364800,
                "headline": "Correction: Zealand Pharma - Transactions related to share buy-back program (week 35, 2026)"
              },
              {
                "id": 141379563,
                "url": "https://finnhub.io/api/news?id=2870c203a702b36bc9de60583eec320e814949a354fd9c25262b9eb825cb345a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Kymera Therapeutics' (KYMR) KT-621 could validate its \"oral Dupixent\" potential, but with a roughly",
                "category": "company",
                "datetime": 1788364753,
                "headline": "Kymera's KT-621 Has 'Oral Dupixent' Potential, but Valuation Limits Upside, RBC Says"
              },
              {
                "id": 141379861,
                "url": "https://finnhub.io/api/news?id=3b81682ec6880284e6626e8db1bcb83438a9191f8627dc5a7e11a9b307df6249",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Ocugen moves OCU410 into phase III for geographic atrophy, with FDA-aligned study plans. The company expects to file a BLA for OCU410 in 2028.",
                "category": "company",
                "datetime": 1788364320,
                "headline": "OCGN Advances Gene Therapy OCU410 In Phase III for Geographic Atrophy"
              },
              {
                "id": 141380073,
                "url": "https://finnhub.io/api/news?id=9599d371dfd9c12612e380fef274055f7ec38a0f90cdf5a7b9d2be5a7f2aff82",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Halozyme (NASDAQ:HALO) will participate in three healthcare investor conferences during September, giving management multiple opportunities to discuss its commercially validated ENHANZE platform and expanding portfolio of drug delivery technologies. Key Investor TakeawaysHalozyme (NASDAQ:HALO) management will participate in investor events hosted by Wells Fargo, Morgan Stanley and H.",
                "category": "company",
                "datetime": 1788363623,
                "headline": "Halozyme Investor Conferences Put ENHANZE and Expanded Drug Delivery Portfolio in Focus"
              },
              {
                "id": 141378299,
                "url": "https://finnhub.io/api/news?id=15e5e776150423d4684ab12b572688ca2579cdf1876eace602510255cdcd6627",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Asian equities traded in the US as American depositary receipts were tracking higher Wednesday morni",
                "category": "company",
                "datetime": 1788363571,
                "headline": "Asian Equities Traded in the US as American Depositary Receipts Rise in Wednesday Trading"
              },
              {
                "id": 141380075,
                "url": "https://finnhub.io/api/news?id=31447003a79c1a77f5924c49a2420f40c40dfe10a0babb799db2d1e8af826803",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "RenovoRx (NASDAQ:RNXT) will use its H. C.",
                "category": "company",
                "datetime": 1788363556,
                "headline": "RenovoRx H.C. Wainwright Presentation to Highlight RenovoCath Growth and Phase III TIGeR-PaC Timeline"
              },
              {
                "id": 141376735,
                "url": "https://finnhub.io/api/news?id=8f2dd41fee60f63e80b68e904f0fcdacabc50151f1c25f0568b40400be52a8d4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Telix Pharmaceuticals Ltd ADR (NASDAQ:TLX) shares rose 5. 3% in premarket trading on Wednesday as investors assessed the company’s Phase 3 BiPASS trial progress and its regulatory pathway in the U.",
                "category": "company",
                "datetime": 1788360974,
                "headline": "Telix Pharmaceuticals Shares Rise 5.3% as Analyst Highlights BiPASS Trial and FDA Pathway"
              },
              {
                "id": 141376199,
                "url": "https://finnhub.io/api/news?id=8516fefd2a35173aa62476707580400a1db2e41384346018cfcd8590df085ca6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Sirius XM upgraded, Toast downgraded: Wall Street's top analyst calls",
                "category": "company",
                "datetime": 1788360888,
                "headline": "Sirius XM upgraded, Toast downgraded: Wall Street's top analyst calls"
              },
              {
                "id": 141377875,
                "url": "https://finnhub.io/api/news?id=d19898cf90032682f64621ae3938cb046cb715687f4b4abde95078cab151d2d1",
                "image": "https://www.chartmill.com/images/uploads/CM_Gap_Stocks_Small_free_ad767b11cf.webp",
                "source": "ChartMill",
                "related": "MRNA",
                "summary": "Let's take a look at the S&P500 stocks that are experiencing notable price gaps in today's session on Wednesday. Discover the gap up and gap down stocks in the S&P500 index.",
                "category": "company",
                "datetime": 1788359701,
                "headline": "Wednesday's session: gap up and gap down stock in the S&P500 index"
              },
              {
                "id": 141376748,
                "url": "https://finnhub.io/api/news?id=2bb6090fbc1907fa07166d09c465dee1724d2d4a211bd228699401558f43aa38",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "AstraZeneca reports positive SANOVO data, showing Tagrisso plus Orpathys improved PFS in first-line EGFR-mutated NSCLC.",
                "category": "company",
                "datetime": 1788358800,
                "headline": "AZN's Tagrisso Plus Orpathys Study in First-Line NSCLC Meets Goal"
              },
              {
                "id": 141376750,
                "url": "https://finnhub.io/api/news?id=42a0002644172783d8213beb012f040e7c4480ebe809664ef6e240172ae03de0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "This Strategic Engagement is Designed to Strengthen NeuroThera's U.S. Market Position, Visibility Among Key U.S. Federal Stakeholders, Reinforce the Clinical and PublicHealth Importance of Advancing New Treatment Options for Adult Tourette Syndrome T...",
                "category": "company",
                "datetime": 1788358611,
                "headline": "SciSparc: Subsidiary NeuroThera Labs Pursues FDA Orphan Drug Designation for Adult Tourette Syndrome Drug; Engages Government and Public Affairs Firm RK Strategies"
              },
              {
                "id": 141376751,
                "url": "https://finnhub.io/api/news?id=d118cf1ab3728ebf1b85979981ec53e439dc21f0386a451d7ff93199e67f6195",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "The recent breakout of Moderna reminded investors that AI stocks aren’t the only destination to make money. Healthcare and biotech stocks offer promising long-term opportunities if chosen wisely. We ran an analysis based on Insider Monkey’s proprietary database of over 900 hedge funds to see which healthcare stocks trading under $20 billionaire-led funds were holding […]",
                "category": "company",
                "datetime": 1788358558,
                "headline": "Billionaire Portfolios: 2 Under-$20 Healthcare Stock Picks"
              },
              {
                "id": 141377129,
                "url": "https://finnhub.io/api/news?id=0524f5341c811d3836ae53e77f448b8fe9dac495650fa53cc5ed549aad326309",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "RAMAT GAN, Israel, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF) (“Can-Fite” or the “Company”), a clinical-stage biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and inflammatory diseases, today announced the entry into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 1,591,738 American Depositary Shares (ADSs), having an exercise",
                "category": "company",
                "datetime": 1788357720,
                "headline": "Can-Fite Announces Exercise of Warrants for Approximately $4.0 Million in Gross Proceeds"
              },
              {
                "id": 141377131,
                "url": "https://finnhub.io/api/news?id=38d66946ffb9306ff91b275362767a12a7cd3dd6e6aa7b07180d1b3ad658deae",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "HCW9302 is a best-in-class IL-2-based immunotherapeutic for treatment of autoimmune diseases through expanding and activating regulatory T cells Patent allowance received for use of HCW9302 as treatment for alopecia areata Phase 1 dose-escalating clinical study evaluating HCW9302 as monotherapy in patients with alopecia areata on track for completion in Q4 2026, continues to be well tolerated with no dose-limiting toxicities Preliminary readout of first two dose cohorts is encouraging -- patient",
                "category": "company",
                "datetime": 1788357600,
                "headline": "HCW Biologics Strengthens U.S. Patent Estate for Its Lead Clinical-Stage Immunotherapeutic HCW9302 as Alopecia Areata Treatment"
              },
              {
                "id": 141377130,
                "url": "https://finnhub.io/api/news?id=622208655f422ef0a7b3070b74a7094949638e925269383778f9885a9e81c75d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that management will present at upcoming investor conferences in September.",
                "category": "company",
                "datetime": 1788357600,
                "headline": "BioMarin to Participate in Upcoming Investor Conferences"
              },
              {
                "id": 141377132,
                "url": "https://finnhub.io/api/news?id=947ee2dadcd3fd77b274c5e65dc7bd3ca7582f8c10d1832258adf6bc883791d0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Patent protections establish long-duration intellectual property coverage for Ampligen across major European markets and the United Kingdom Latest milestone further strengthens AIM’s expanding global Ampligen patent estate across multiple therapeutic opportunities Follows newly issued U.S. patent covering Ampligen in combination with pembrolizumab for the treatment of cancer OCALA, Fla., Sept. 02, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today an",
                "category": "company",
                "datetime": 1788356580,
                "headline": "AIM ImmunoTech Significantly Expands Ampligen® Global Patent Estate with Long COVID Protection Across Europe and the United Kingdom Through 2041"
              },
              {
                "id": 141377133,
                "url": "https://finnhub.io/api/news?id=b9edb4df673664de529b95d662e9c66c8a644b481eca63466b3590767244e78c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Immunic Inc (NASDAQ:IMUX, FRA:10VA) announced that it will host a virtual research and development day focused on relapsing multiple sclerosis on September 9, as the biotechnology company prepares for topline results from its Phase 3 ENSURE trials expected by the end of 2026. The event will...",
                "category": "company",
                "datetime": 1788356400,
                "headline": "Immunic to host virtual relapsing MS R&D Day on September 9"
              },
              {
                "id": 141379150,
                "url": "https://finnhub.io/api/news?id=fac6b53077cb17d7af20e819aacca07cf62593653b986be157b110f4bed8e7fd",
                "image": "https://cdn.benzinga.com/files/images/story/2025/11/06/aggregated_options_3.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "This whale alert can help traders discover the next big trading opportunities.\nWhales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.\nTraders often",
                "category": "company",
                "datetime": 1788356125,
                "headline": "10 Health Care Stocks Whale Activity In Today’s Session"
              },
              {
                "id": 141377134,
                "url": "https://finnhub.io/api/news?id=caa364fedebabb3cb1d89ee60f060a117dfa4d0ef480c4f694d186ca28cfd506",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "LOS ANGELES, September 02, 2026--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces that senior management will participate at the Longevity Investors Conference, taking place from September 14 to 17, 2026, in Gstaad, Switzerland.",
                "category": "company",
                "datetime": 1788355920,
                "headline": "Niagen Bioscience to Present at Longevity Investors Conference"
              },
              {
                "id": 141377135,
                "url": "https://finnhub.io/api/news?id=36a8623a538a68b73d1d6f02da9374a9ea6f758aeb4e1f19984c3ffe6c244523",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "TScan Therapeutics (NASDAQ:TCRX) announced a strategic reorganization that includes a workforce reduction of approximately 75% as the company redirects resources toward an in vivo-engineered T cell receptor, or TCR-T, program targeting solid tumors. The Waltham, Massachusetts-based company plans to advance two product candidates into investigational new drug-enabling studies.",
                "category": "company",
                "datetime": 1788355841,
                "headline": "TScan Therapeutics Cuts Workforce by 75% and Shifts Focus to Solid Tumor Program"
              },
              {
                "id": 141377144,
                "url": "https://finnhub.io/api/news?id=dd7fc1d4563686c52b23da2a382f8b0d2c01f11d68df2e726da60fc7b59c7192",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "MOUNTAIN VIEW, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared drug-delivery device, today announced that Shaun Bagai, Chief Executive Officer, and Mark Voll, Chief Financial Officer, will present at the H.C. Wainwright 28th Annual Global Investment Conference. The conference will be held at the Lotte New York P",
                "category": "company",
                "datetime": 1788355800,
                "headline": "RenovoRx to Present at H.C. Wainwright 28th Annual Global Investment Conference, September 14th-16th"
              },
              {
                "id": 141377143,
                "url": "https://finnhub.io/api/news?id=772837100d21bf8d739f2e14075dbd2c267c6fa04a859bfc69f1015c29dc8735",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "SAN DIEGO, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with debilitating autoimmune diseases, today announced that management will participate at the following investor conferences: 2026 Cantor Global Healthcare Conference – live fireside chat on Wednesday, September 9, 2026 at 10:20 am EDTH.C. Wainwright 28th Annual Global Inv",
                "category": "company",
                "datetime": 1788355800,
                "headline": "Artiva Biotherapeutics to Participate in Upcoming Investor Conferences in September"
              },
              {
                "id": 141377141,
                "url": "https://finnhub.io/api/news?id=0cbcc30bf88e4c9c7bc14cbd45589e79ea9ef6a07c585d6269f8712981898429",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "- Three posters to highlight preclinical activity of SLS009 (tambiciclib) across patient-derived KRAS mutant organoid models of pancreatic cancer – - Studies conducted in collaboration with the University of Wisconsin School of Medicine and Public Health - NEW YORK, Sept. 02, 2026 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer",
                "category": "company",
                "datetime": 1788355800,
                "headline": "SELLAS Life Sciences to Present Preclinical Data on SLS009 in Pancreatic Ductal Adenocarcinoma at the 2026 AACR Conference on Pancreatic Cancer"
              },
              {
                "id": 141377140,
                "url": "https://finnhub.io/api/news?id=89398142b09f6faf75560b6fe8fadc3498b45b3620e792176ce3217719f377ad",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), today announced that members of the MannKind management team will present at the following upcoming investor conferences: Cantor Global Healthcare Conference (New York, NY)Fireside Chat, Thursday, September 10, 2026, at 11:30 a.m. ET H.C. Wainwright 28th Annual Global Investment Conference (New York, NY)Fireside Chat, Tuesday, September 15, 2026, at 9:30 a.m. ET Links to the live",
                "category": "company",
                "datetime": 1788355800,
                "headline": "MannKind to Present at Upcoming Investor Conferences"
              },
              {
                "id": 141377139,
                "url": "https://finnhub.io/api/news?id=8708117480a5ef06996f24a6ca480f7508874446cab592ecd6bf0d10edddef2f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "MINNEAPOLIS, September 02, 2026--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, today announced that company management will participate in four upcoming investment bank conferences in New York.",
                "category": "company",
                "datetime": 1788355800,
                "headline": "DiaMedica Therapeutics to Participate in Upcoming September Investor Conferences"
              },
              {
                "id": 141377138,
                "url": "https://finnhub.io/api/news?id=eb9d71d961bc203571254c4cfda6bafc6ad923d0e7d61a9c8684f20850c71993",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "LA JOLLA, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that management will participate in the following upcoming investor conferences: Cantor Global Healthcare Conference 2026Format: Fireside Chat & 1x1 MeetingsDate: Wednesday, September 9, 2026Time: 9:45 AM EDTWebcast Link: Here H.C. Wainwright 28th Annual Global Investment ConferenceFormat: Co",
                "category": "company",
                "datetime": 1788355800,
                "headline": "Equillium to Participate in Upcoming Investor Conferences"
              },
              {
                "id": 141377137,
                "url": "https://finnhub.io/api/news?id=cbd59e8e27c49b8540587f5d760f4091855bef8d3041c54690f1756e28153bf1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "SAN DIEGO, CA / ACCESS Newswire / September 2, 2026 / , Inc. (NASDAQ:ENSC) (\"Ensysce\" or the \"Company\") a clinical-stage biotechnology company developing novel neuroplastogenic therapies beyond mood disorders, with an initial focus on CRPS (Complex Regional Pain Syndrome), today announced its participation in the following upcoming investors conferences and industry events.",
                "category": "company",
                "datetime": 1788355800,
                "headline": "Ensysce Biosciences Announces Upcoming Conference and Industry Event Participation"
              },
              {
                "id": 141377136,
                "url": "https://finnhub.io/api/news?id=a8ff1720707c68c2d21049f11bfd1b1812d4bd2ddb8ddb0a58cc70d128807394",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "SOUTH SAN FRANCISCO, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today announced that Geoffrey Parker, Executive Vice President and Chief Financial Officer, will retire effective November 6, 2026. Mr. Parker will continue to lead the finance organization through his retirement date as the Company conducts an exter",
                "category": "company",
                "datetime": 1788355800,
                "headline": "Allogene Therapeutics Announces Retirement of Chief Financial Officer Geoffrey Parker"
              },
              {
                "id": 141375829,
                "url": "https://finnhub.io/api/news?id=410e1a48574b90cabce85bb7f1db432edb133ccc6b0b3ce970d9a46d2c981532",
                "image": "https://www.chartmill.com/images/uploads/CM_Premarket_Movers_Small_free_90289f6b81.webp",
                "source": "ChartMill",
                "related": "MRNA",
                "summary": "Wondering what's happening in today's pre-market session? Stay tuned for the latest updates on S&P500 stock movements.",
                "category": "company",
                "datetime": 1788352501,
                "headline": "Wednesday's pre-market session: top gainers and losers in the S&P500 index"
              },
              {
                "id": 141378132,
                "url": "https://finnhub.io/api/news?id=d7b4a1950695fc7c9056daeba33ef9e9449cfd639a5066e79700e549630ab9a1",
                "image": "https://cdn.benzinga.com/files/images/story/2026/09/02/Moderna-Inc.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "Shares of Moderna Inc (NASDAQ: MRNA) are trading lower Wednesday morning, taking a breather following a 170% surge over the trailing month.",
                "category": "company",
                "datetime": 1788345738,
                "headline": "Moderna Stock Moves Lower Wednesday: What's Going On?"
              },
              {
                "id": 141373301,
                "url": "https://finnhub.io/api/news?id=24eef22228eed8ffbd8091caadf478dcbe7eea4e653e52b0d457f9066f730f6f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Vertex Pharmaceuticals stock has delivered strong multi year gains, and current valuation checks suggest the shares now look closer to fairly priced than clearly cheap or clearly expensive. Vertex Pharmaceuticals has returned 184.9% over the past 5 years, which puts extra focus on whether the current price still offers an appealing entry point for new money. Expectations for continued revenue and cash flow growth from its existing treatment portfolio can support today’s valuation, while any...",
                "category": "company",
                "datetime": 1788314840,
                "headline": "Vertex (VRTX) Stock Trades At A Premium On Earnings Yet Looks Fair On Broader Checks"
              },
              {
                "id": 141373302,
                "url": "https://finnhub.io/api/news?id=66e099b1e7da169967624de7aedb9f6901aa6034b42d3bcd2a797f9766d16602",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Two of healthcare’s most pressing challenges - the growing prevalence of diabetes and rising antibiotic resistance - are converging in diabetic foot infections, where slow-healing wounds can develop into serious infections, hospitalisation and amputation. The International Diabetes Federation...",
                "category": "company",
                "datetime": 1788313140,
                "headline": "Recce Pharmaceuticals advances R327 as diabetes and antibiotic resistance burdens converge"
              },
              {
                "id": 141373098,
                "url": "https://finnhub.io/api/news?id=3b8ae9abd0431d10053f8279b998a980036723c7d887184dd5f43c60a6006a14",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "In August 2026, Merck & Co., Inc. and Moderna, Inc. reported that their Phase 3 INTerpath-001 trial of individualized mRNA therapy intismeran autogene plus KEYTRUDA in completely resected stage IIB–IV melanoma met its primary and key secondary endpoints, improving recurrence-free and distant metastasis-free survival versus KEYTRUDA alone with no new safety issues identified. This marks the first positive Phase 3 outcome for both an individualized neoantigen therapy and an mRNA-based cancer...",
                "category": "company",
                "datetime": 1788311942,
                "headline": "Did Merck’s (MRK) First Positive Phase 3 Individualized mRNA Cancer Trial Just Redefine Its Moat?"
              },
              {
                "id": 141373304,
                "url": "https://finnhub.io/api/news?id=69b7472681737818ebf952176673daae5b1fc9ae52427b529f40bbcfd12ffb45",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "The selloff followed topline results from the Phase 2b LUMUS trial of envudeucitinib in moderate-to-severe systemic lupus erythematosus, or SLE, a chronic autoimmune disease in which the body's immune system mistakenly attacks healthy tissues.",
                "category": "company",
                "datetime": 1788310512,
                "headline": "ALMS Stock Clocks Worst Day After 57% Drop — What Drove The Selloff?"
              },
              {
                "id": 141373306,
                "url": "https://finnhub.io/api/news?id=1d72c9067f702f968a1215373b804800c6ba313a63ace7b0e34fb6978b6dfbed",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Protagonist Therapeutics stock has delivered very strong returns over the past few years, yet the broader valuation checks currently lean toward the shares looking expensive rather than like an obvious bargain. After such a strong move, investors are weighing how much of the good news is already reflected in the price. Over the past 3 years, Protagonist Therapeutics has gained roughly 6.5 times its earlier level. This puts extra focus on whether recent enthusiasm has pushed the valuation...",
                "category": "company",
                "datetime": 1788307621,
                "headline": "Protagonist Therapeutics (PTGX) Stock Could Be Overvalued Following FDA Approval News"
              },
              {
                "id": 141373307,
                "url": "https://finnhub.io/api/news?id=188bb6b727ebbe4cb6585f90cb7bb0c7c4c2c6b86cf7eb77b011a3aef842952d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES. TORONTO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FSE: 0K91) (Upstream: QNTM) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and meta",
                "category": "company",
                "datetime": 1788307200,
                "headline": "Quantum BioPharma Announces Plans to Voluntarily Delist its Class B Shares from the Canadian Securities Exchange"
              },
              {
                "id": 141373310,
                "url": "https://finnhub.io/api/news?id=405b8906cdcf4ce2ecc795723bb2d54da4f33fdaa2492fe45bde7e39e0c53778",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "The Phase 3 BiPASS™ study of Illuccix® and Gozellix® for prostate cancer imaging in the pre-biopsy setting has completed enrollment of 350 patients.Telix has positively engaged with the FDA on a New Drug Application (NDA) pathway in the U.S. that would support new product reimbursement and broaden access to 68Ga-PSMA-PET imaging across a significantly larger patient population.BiPASS is designed to evaluate the diagnostic performance of 68Ga-PSMA-11 PET combined with MRI for the detection of pro",
                "category": "company",
                "datetime": 1788304680,
                "headline": "Telix Completes Enrollment in Phase 3 BiPASS Study, Aligns with FDA on NDA Pathway"
              },
              {
                "id": 141373312,
                "url": "https://finnhub.io/api/news?id=86efe8a544b056ba673a7a56ff828552c93c09cc25bb77cf3d8740408a14a094",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Dogwood Therapeutics (NASDAQ:DWTX) said its Phase 2b study of Halneuron, an investigational treatment for chemotherapy-induced neuropathic pain, has enrolled more than 230 patients and is expected to report top-line data later this fall. During a virtual key opinion leader event, Chief Executive Of",
                "category": "company",
                "datetime": 1788303718,
                "headline": "Dogwood Therapeutics Nears Phase 2b Readout for Halneuron Neuropathic Pain Treatment"
              },
              {
                "id": 141373317,
                "url": "https://finnhub.io/api/news?id=ded2ad67c9e139b7de51ed6a8abea8af32fdc5bcc04e11195a20d9b827c3f671",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Fractyl Health (NASDAQ:GUTS) outlined a commercial strategy for its investigational Revita procedure, positioning the one-time endoscopic therapy as a potential option for patients seeking to maintain weight loss after discontinuing GLP-1 medicines. The company said Revita is designed for post-GLP-",
                "category": "company",
                "datetime": 1788300118,
                "headline": "Fractyl Health Eyes 2028 Revita Launch for Post-GLP-1 Weight Maintenance"
              },
              {
                "id": 141373243,
                "url": "https://finnhub.io/api/news?id=1d09fe56b3f2ae0118219bded7a24f374ac8cd0974c7fd84f81443e44217ae6e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Calgary, Alberta--(Newsfile Corp. - September 1, 2026) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the \"Company\" or \"Marvel\"), announces the award of 50,001 deferred share units (\"DSUs\") to Marvel's three independent directors, in lieu of cash payment for directors' fees.The DSUs will all vest on September 1, 2027. Vested DSUs shall be settled upon the directors' separation from service from the Company and expire 365 days...",
                "category": "company",
                "datetime": 1788300060,
                "headline": "Marvel Biosciences Announces Grant of Deferred Share Units"
              },
              {
                "id": 141373176,
                "url": "https://finnhub.io/api/news?id=581efa284d9259a80c322598ff107974b355a2466f8ac59a5d624d6c9863f0de",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Impressive results came out on drugs from Amgen, Arrowhead Pharmaceuticals, and Crispr Therapeutics. Their shares are all lower this week.",
                "category": "company",
                "datetime": 1788298920,
                "headline": "Heart-Drug Breakthroughs Can’t Stop Biotech Stocks From Sliding"
              },
              {
                "id": 141373207,
                "url": "https://finnhub.io/api/news?id=aebc6f5f254a097d43b733a17dd777d8d87d0d9f749857831eaeb1b3ede7062f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "None of the underlying conditions that sent Sandisk to its all-time high earlier this year have changed.",
                "category": "company",
                "datetime": 1788298731,
                "headline": "Down More Than 30% From Its Peak, Is Now the Perfect Time to Buy Sandisk Stock?"
              },
              {
                "id": 141373520,
                "url": "https://finnhub.io/api/news?id=95ec0077bad688f140bfdecda5ff2b01b25dd9d3e56a77e847e97291d9688e90",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "BOSTON, Sept. 01, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced that, effective on August 31, 2026, the company issued inducement awards to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan (the “2019 Inducement Plan”). The 2019 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of X",
                "category": "company",
                "datetime": 1788298200,
                "headline": "X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)"
              },
              {
                "id": 141372994,
                "url": "https://finnhub.io/api/news?id=4b529d1677e7a39ffbaafeb250ed30ca75f846603aecaf2652f83dc89976ee6e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Tesla trades lower even as investors anticipate the potential entry of Cybercab into the company’s fleet of self-driving cabs.",
                "category": "company",
                "datetime": 1788297840,
                "headline": "Tesla, Apple, Nvidia, Medtronic, Alumis, Robinhood, Fervo, and More Stocks That Explain Today’s Market"
              },
              {
                "id": 141373522,
                "url": "https://finnhub.io/api/news?id=154226d93177727a24fc72e34b08c366173385fb448a05ad6887634e9faf2347",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "TGTX shares opened lower on Tuesday after Novartis said its drug remibrutinib improved multiple sclerosis in late-stage trials.",
                "category": "company",
                "datetime": 1788294470,
                "headline": "TGTX Stock Pares Opening Losses After Analyst Dismisses Competition From Novartis"
              },
              {
                "id": 141370622,
                "url": "https://finnhub.io/api/news?id=e4e668cf4e2ac66b32d64d766ef87081023c2f7289adb9dd0d8bab424e26118e",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "MRNA",
                "summary": "Stay updated with the movements of the S&P500 index one hour before the close of the markets on Tuesday. Discover which stocks are leading as top gainers and losers in today's session.",
                "category": "company",
                "datetime": 1788289501,
                "headline": "Exploring the top movers within the S&P500 index during today's session."
              },
              {
                "id": 141369875,
                "url": "https://finnhub.io/api/news?id=25713ea44798b5c5338ef99e3f48cdcdce18c543fa8e5a8f3d3b44d5e44b9a8a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "GSK just handed Moderna's biggest rival program a late-stage green light, yet traders are sending MRNA stock sharply higher. The logic behind that reaction tells you something important about where the real value of mRNA technology sits right now.",
                "category": "company",
                "datetime": 1788289217,
                "headline": "Moderna Rises 6% Despite GSK Moving Rival mRNA Flu Vaccine to Phase III"
              },
              {
                "id": 141370154,
                "url": "https://finnhub.io/api/news?id=b0755610ee72c181e96b2525c1aa0f0c8edd478419b4c03e0b9346066b831860",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Retail traders are piling into Novavax on cancer-vaccine speculation, but the move that actually changed the company's business model happened quietly last week and has nothing to do with oncology.",
                "category": "company",
                "datetime": 1788286333,
                "headline": "Novavax Jumps 6% on Matrix-M Oncology Speculation: Is the Royalty Model the Real Story?"
              },
              {
                "id": 141369838,
                "url": "https://finnhub.io/api/news?id=f54682b0be71e2c22431932fafa4cec47274c5af0413a26f923d05835763f1d9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Equity Insider News Commentary - The global medical aesthetics market has quietly become one of the most durable growth stories in healthcare. Multiple market-research firms size it at roughly US$22 billion to US$23 billion in 2026, with projections reaching approximately US$40 billion by 2031 at a compound annual growth rate near 12 percent, and other forecasts running higher still over longer horizons. The drivers are structural: an aging population, rising disposable incomes, the normalizatio",
                "category": "company",
                "datetime": 1788280620,
                "headline": "A Wave of Weight-Loss Drugs Is Quietly Creating a Multi-Billion-Dollar Opportunity That Aesthetic Medicine Is Racing to Capture"
              },
              {
                "id": 141368964,
                "url": "https://finnhub.io/api/news?id=e5186e485dc68957760302a6c425447b90b006aca680e1528a0a389ed7c70459",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "MRNA",
                "summary": "Stay informed about the performance of the S&P500 index in the middle of the day on Tuesday. Uncover the top gainers and losers in today's session for valuable insights.",
                "category": "company",
                "datetime": 1788280501,
                "headline": "Which S&P500 stocks are moving on Tuesday?"
              },
              {
                "id": 141370152,
                "url": "https://finnhub.io/api/news?id=f86d44cb82236c69122d005e9c5e9f7c64e419799f3177838060b84f5d2e99d9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "The company progresses its mRNA-based candidate just under a month after Moderna won FDA approval for the first seasonal flu mRNA vaccine.",
                "category": "company",
                "datetime": 1788279133,
                "headline": "GSK hopes to take on Moderna as it moves mRNA flu vaccine to Phase III trial"
              },
              {
                "id": 141373123,
                "url": "https://finnhub.io/api/news?id=a7eacfeca284fc4fc2b2ec21f691424337fff6ec3584410008d02195ff61ac52",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "European equities traded in the US as American depositary receipts were trending slightly higher lat",
                "category": "company",
                "datetime": 1788279014,
                "headline": "European Equities Traded in the US as American Depositary Receipts Edge Higher in Tuesday Trading"
              },
              {
                "id": 141369873,
                "url": "https://finnhub.io/api/news?id=1bce6207890c6536b7e9eb485b632e6b759d6d03e2e31443e056c8d59c8c4270",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Merck-Moderna's melanoma vaccine success could boost immunotherapy growth, putting healthcare ETFs in the spotlight.",
                "category": "company",
                "datetime": 1788276420,
                "headline": "Healthcare ETFs to Watch Post Merck-Moderna Cancer Vaccine Breakthrough"
              },
              {
                "id": 141361968,
                "url": "https://finnhub.io/api/news?id=e96871172873d0ee356a7582203752db199b30a6eb4d6edec1aa55a84808e45f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "New molecular imaging capabilities connect longitudinal radiopharmaceutical uptake with biodistribution, efficacy and clinically annotated PDX tumor biology in a single, U.-based workflowHACKENSACK, NJ / ACCESS Newswire / September 1, 2026 / , a leading provider of translational oncology research solutions, today announced the expansion of its integrated radiopharmaceutical development platform with new in-house SPECT/CT imaging capabilities.",
                "category": "company",
                "datetime": 1788271200,
                "headline": "Champions Oncology Expands Integrated Radiopharmaceutical Development Platform with In-House SPECT/CT Imaging"
              },
              {
                "id": 141361001,
                "url": "https://finnhub.io/api/news?id=9315fd4dd75780eaab7805f262d6a791796b33062bb781fa99191d618e904bc8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna stock led the index after melanoma vaccine data, while a hedge fund's forced unwind turbocharged a rebound in enterprise software",
                "category": "company",
                "datetime": 1788269873,
                "headline": "S&P 500 biggest August 2026 winners: Moderna, software stocks"
              },
              {
                "id": 141369187,
                "url": "https://finnhub.io/api/news?id=efc3da274f0ad5bd69acce8293e14118c2980c701e25a977ad4af86808ec1c51",
                "image": "https://cdn.benzinga.com/files/images/story/2026/09/01/New-York-Ny-Usa-march-21--2024-The-New-Y.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "The 10-year Treasury yield hit a 19-month high and crude jumped above $88 as traders lifted Fed rate-hike odds to 68%, cracking high-multiple software stocks.",
                "category": "company",
                "datetime": 1788267096,
                "headline": "Oil Surges, Treasury Yields Climb a Fifth Day, Software Retreats: Stock Market Today"
              },
              {
                "id": 141369496,
                "url": "https://finnhub.io/api/news?id=4f91f46ba2696ef86a00fd668abea30ee391a07d5822b5a8219287f5f296dad8",
                "image": "https://cdn.benzinga.com/files/images/story/2026/09/01/Skin-Cancer-Risk-Remains-High.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "Moderna’s cancer vaccine breakthrough puts biotech, mRNA and genomics ETFs in focus. Here are the funds worth watching.",
                "category": "company",
                "datetime": 1788265512,
                "headline": "Next Biotech Boom May Be Cancer Vaccines: Watch These ETFs"
              },
              {
                "id": 141363874,
                "url": "https://finnhub.io/api/news?id=53e44afe04d248eabe67f3914aea3a4201319606aa1174939a08b8bec3b9d18a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "CAMBRIDGE, MA / ACCESS Newswire / September 1, 2026 / (Nasdaq:MRNA), today announced its participation in the following upcoming investor conferences: * Morgan Stanley 24th Annual Global Healthcare Conference, on Monday, September 14 at 10:00 a. ET * Bernstein Insights: Healthcare Leaders and Disruptors 3rd Annual Healthcare Forum, on Wednesday, September 23 at 8:50 a.",
                "category": "company",
                "datetime": 1788264000,
                "headline": "Moderna to Present at Upcoming Conferences in September 2026"
              },
              {
                "id": 141361973,
                "url": "https://finnhub.io/api/news?id=0130ee39f7dfd1f43695963ea74fc623b987ab75d42d7dd455164ebada20aee6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Immunocore to present at upcoming investor conferences (OXFORDSHIRE, England & RADNOR, PA & GAITHERSBURG, MD, US, 1 September 2026) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced management will participate at the following conferences in September.",
                "category": "company",
                "datetime": 1788264000,
                "headline": "Immunocore to present at upcoming investor conferences"
              },
              {
                "id": 141361971,
                "url": "https://finnhub.io/api/news?id=068d1188e6a5b78f43a72199c6a68e9fce37d4d5912d89540eeb6b71bdd641de",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "– Following productive FDA discussions, Upstream Bio will study 400 mg of verekitug administered every 12 weeks, versus placebo, in severe asthma and CRSwNP with one pivotal Phase 3 trial in each indication – – The Company’s Phase 3 strategy is designed to deliver best-in-class efficacy across both indications by evaluating a high-dose, quarterly regimen of verekitug in broad patient populations – – The Company remains on track to initiate both Phase 3 trials in Q1 2027 – WALTHAM, Mass., Sept. 0",
                "category": "company",
                "datetime": 1788264000,
                "headline": "Upstream Bio Announces Pivotal Phase 3 Development Plans for Verekitug in Both Severe Asthma and CRSwNP"
              },
              {
                "id": 141378135,
                "url": "https://finnhub.io/api/news?id=c43b191721567e12664a5075a389a612564e21a4d09ac213aa744e81786a9f32",
                "image": "https://cdn.benzinga.com/files/images/story/2026/09/01/Moderna-vaccine.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "Moderna Inc (NASDAQ: MRNA) shares are trading higher Tuesday morning. Here's what investors need to know.",
                "category": "company",
                "datetime": 1788262053,
                "headline": "Moderna Stock Climbs Tuesday: What's Going On?"
              },
              {
                "id": 141360929,
                "url": "https://finnhub.io/api/news?id=850fd776842a9c5d07f1f1707f7c659b106fea0258106098bb8e97ec28b41bc4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "A surplus of cash can mean financial stability, but it can also indicate a reluctance (or inability) to invest in growth. Some of these companies also face challenges like stagnating revenue, declining market share, or limited scalability.",
                "category": "company",
                "datetime": 1788261020,
                "headline": "1 Cash-Heavy Stock on Our Buy List and 2 Facing Challenges"
              },
              {
                "id": 141361116,
                "url": "https://finnhub.io/api/news?id=00d5e7c3f39d64edeb80638ea6187af7e328a3c5e29fd488b3fc67e6c2ccf850",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "The company may be on track to its next product.",
                "category": "company",
                "datetime": 1788253801,
                "headline": "Moderna Stock More Than Doubled in August. Is the Stock a Buy, a Hold, or a Sell?"
              },
              {
                "id": 141361111,
                "url": "https://finnhub.io/api/news?id=84a3369fca40d74a20da124b5e8d22c4b306dc479750442df4f31fc296463d5a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna Inc. (NASDAQ:MRNA) saw its share price soar by 156 percent in August—making it the highest-gaining stock for the month—driven primarily by the strong clinical trial results of its therapy candidate for melanoma, supported by a recent regulatory approval for its updated COVID-19 vaccines. It can be recalled that Moderna and Merck recently partnered for […]",
                "category": "company",
                "datetime": 1788245094,
                "headline": "Moderna (MRNA) Soars 156% in August — Here’s What Propelled The Rally"
              },
              {
                "id": 141361975,
                "url": "https://finnhub.io/api/news?id=20f6c0ad23b56a9f40452917e323e7d70442f17e0b5a5d112aa3fff69a505688",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "MENLO PARK, Calif., August 31, 2026--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics derived from its boron chemistry platform, today announced that four abstracts highlighting clinical and nonclinical data supporting the development of epetraborole, a novel boron-containing oral candidate for the treatment of polycythemia vera (PV), will be presented at the Society of Hematologic Onco",
                "category": "company",
                "datetime": 1788217200,
                "headline": "AN2 Therapeutics Presents Clinical and Translational Data Supporting Development of Epetraborole for Polycythemia Vera at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting"
              },
              {
                "id": 141361004,
                "url": "https://finnhub.io/api/news?id=3019349918a84a22c501c1094747caeb08aef1bd487fab04745c235c585dc2cc",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "The energy and technology sectors did well in August, while Moderna’s stock was the best performer by a wide margin.",
                "category": "company",
                "datetime": 1788214560,
                "headline": "23 best-performing stocks of August, as the software industry continues its recovery"
              },
              {
                "id": 141361117,
                "url": "https://finnhub.io/api/news?id=6593cd0517ad32cbdb541210175453331bb3059dc150c87637f7d4fc6e86bbc2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna stock surged 158% in August to lead the S&P 500, while Edison International plunged 27% to rank last in the index.",
                "category": "company",
                "datetime": 1788213900,
                "headline": "There Was No Beating Moderna in August. These Are the Best and Worst S&P 500 Stocks for the Month."
              },
              {
                "id": 141369353,
                "url": "https://finnhub.io/api/news?id=0f34cad777d099563bf64402c161a3e79f248a4523ac51a0bd5cd7a6b8703058",
                "image": "https://image.cnbcfm.com/api/v1/image/108356753-2ED3-MM-A-BLOCK-083126.jpg?v=1788215951&w=1920&h=1080",
                "source": "CNBC",
                "related": "MRNA",
                "summary": "'Mad Money' host Jim Cramer shares his top 10 stocks from August.",
                "category": "company",
                "datetime": 1788203318,
                "headline": "Jim Cramer talks his top stocks for the month of August"
              },
              {
                "id": 141369354,
                "url": "https://finnhub.io/api/news?id=76663bd9dbf50f0a57b68bff1f12679f1a9c32e1fe296c4e25d4cc54c90a95f0",
                "image": "https://image.cnbcfm.com/api/v1/image/108356754-2ED3-MM-A-BLOCK-SHORT-083126.jpg?v=1788215964&w=1920&h=1080",
                "source": "CNBC",
                "related": "MRNA",
                "summary": "'Mad Money' host Jim Cramer shares his top 10 stocks from August.",
                "category": "company",
                "datetime": 1788203247,
                "headline": "I don't know how Super Micro keeps coming back, says Jim Cramer"
              },
              {
                "id": 141361469,
                "url": "https://finnhub.io/api/news?id=34e30cd031c810d63415f91661c6455830424a81e544234aa232e3fa4a773e73",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "By Mike Sheikh Cocrystal Pharma (NASDAQ: COCP) may look like another undercapitalized, clinical-stage biotech searching for its niche, and in need of a rescue, but there is more to this story than what meets the eye. Investors glancing at the stock chart may miss the signs of a strategic reset orchestrated by biotech legends, and miss […] The post Cocrystal Pharma: The Strategic Reset Investors May Be Missing appeared first on ExecEdge.",
                "category": "company",
                "datetime": 1788194343,
                "headline": "Cocrystal Pharma: The Strategic Reset Investors May Be Missing"
              },
              {
                "id": 141355523,
                "url": "https://finnhub.io/api/news?id=66cd2776f7c30a964722094b09bd6a18e34943fce0381882ba1635f3c58fe405",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "MRNA",
                "summary": "Curious about the top performers within the S&P500 index in the middle of the day on Monday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.",
                "category": "company",
                "datetime": 1788194101,
                "headline": "Uncover the latest developments among S&P500 stocks in today's session."
              },
              {
                "id": 141356225,
                "url": "https://finnhub.io/api/news?id=59a441525d8351f9ca682906e1f1184af38874463dd1c92a51d84c67a55ae7f7",
                "image": "",
                "source": "SeekingAlpha",
                "related": "MRNA",
                "summary": "",
                "category": "company",
                "datetime": 1788188253,
                "headline": "Trump Admin To Target Biotechs With Curbs On Drug Pricing? What Investors Should Know"
              },
              {
                "id": 141363880,
                "url": "https://finnhub.io/api/news?id=c846ea17403deccee94aece98d186165f5597da7a627bfe82a0bba0e6fbbe6d4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "August turned out to be a pretty good month for S&P 500 investors. And some stocks wound up having a great month.",
                "category": "company",
                "datetime": 1788181203,
                "headline": "8 Stocks Turn $100,000 Into $12.7 Million In 8 Months"
              },
              {
                "id": 141361979,
                "url": "https://finnhub.io/api/news?id=ca07fb7e6b7c73414e47b6d53d7b24cde37a40047a9f3d4708b8b0844e03c7d9",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "ALISO VIEJO, Calif., Aug. 31, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 as a biosimilar to BOTOX® (onabotulinumtoxinA) for therapeutic use to achieve full-label U.S. market entry, announced today that AEON management will host in-person 1x1 investor meetings at Lake Street Capital Markets’ 10th Annual Best Ideas Growth (BIG10) Conference being held in New York City on Thursday, September 10th, 2026",
                "category": "company",
                "datetime": 1788181200,
                "headline": "AEON Biopharma to Participate in Lake Street Capital Markets’ 10th Annual Best Ideas Growth (BIG10) Conference"
              },
              {
                "id": 141361978,
                "url": "https://finnhub.io/api/news?id=ea9b4d428df5c1aa920883745aa938c94d6714e139b4f9a992cccd1cc8f44530",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "TEL AVIV, Israel, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for immune-fibrotic diseases with high unmet need, today announced that Chief Executive Officer Dr. Adi Mor will deliver a corporate presentation at the H.C. Wainwright 28th Annual Global Investment Conference. Dr. Mor’s prerecorded presentation will be webcast and will be available starting on September 11, 2026 at 7:",
                "category": "company",
                "datetime": 1788181200,
                "headline": "Chemomab Therapeutics to Present at H.C. Wainwright 28th Annual Global Investor Conference"
              },
              {
                "id": 141354409,
                "url": "https://finnhub.io/api/news?id=e386197b227003cb9e35f310b5fc0325463fc3e1e2b3d357927179bcd5d44831",
                "image": "https://www.chartmill.com/images/uploads/CM_Premarket_Movers_Small_free_90289f6b81.webp",
                "source": "ChartMill",
                "related": "MRNA",
                "summary": "Get insights into the top gainers and losers in the S&P500 index of Monday's pre-market session.",
                "category": "company",
                "datetime": 1788179701,
                "headline": "What's going on in today's pre-market session: S&P500 movers"
              },
              {
                "id": 141355051,
                "url": "https://finnhub.io/api/news?id=d92b169b63df4d431d6ca4d3e2a910e2a44404564eff749693f603b009075ae3",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/466613278/image_466613278.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "MRNA",
                "summary": "Big Pharma hits new 52-week highs on strong Q2 results; explore why some lag and which healthcare ETF offers best income risk/reward. Click for more and the picks.",
                "category": "company",
                "datetime": 1788173434,
                "headline": "Big Pharma's Comeback Is Here: Winners, Losers, And 4 ETFs"
              },
              {
                "id": 141361112,
                "url": "https://finnhub.io/api/news?id=d8d9f29d23f8ccc5a8039fb4f8d576454a33559eca689894c965058ad1ebf9a7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "August has been a great month for the shares of Merck & Co., Inc. (NYSE:MRK) and Moderna Inc. (NASDAQ:MRNA), to say the least. The former’s stock closed 12.6% higher and the latter’s stock closed 176% higher on August 19th. The stocks surged after a major announcement from Moderna Inc. (NASDAQ:MRNA) shared the results from its […]",
                "category": "company",
                "datetime": 1788158154,
                "headline": "Jim Cramer Called Moderna Inc. (NASDAQ:MRNA) & Merck’s Trial Results Encouraging"
              },
              {
                "id": 141363879,
                "url": "https://finnhub.io/api/news?id=54b536fa8bc3106625f0c2d3822de8268fcf77ef546f9427650c0476f2245a1b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna could be on the verge of a breakthrough, but the biotech's MRNA cancer vaccine catalyst is overly priced in.",
                "category": "company",
                "datetime": 1788113100,
                "headline": "Is It Too Late to Buy Moderna Stock After Its 127% Surge?"
              },
              {
                "id": 141361107,
                "url": "https://finnhub.io/api/news?id=604a74c67cc76ee833e91a11b652ccba9c35816d3796c281b4852b3f31915326",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Merck (NYSE:MRK) and Moderna report the first positive Phase 3 results for an individualized mRNA neoantigen cancer therapy in melanoma patients. The therapy was tested in combination with Merck's immunotherapy KEYTRUDA in a Phase 3 trial setting. This marks the first time an mRNA-based individualized neoantigen approach has shown clinically meaningful and statistically significant Phase 3 data in cancer. The result signals a potential new path for personalized cancer vaccines with...",
                "category": "company",
                "datetime": 1788095722,
                "headline": "Merck (MRK) Posts First Positive Phase 3 Result For Personalized mRNA Melanoma Therapy"
              },
              {
                "id": 141339624,
                "url": "https://finnhub.io/api/news?id=44cf81c569d9ca518128cd7ce1b63abb0cdaab2e4a4b7891731afcb9cd738ed8",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2291247270/image_2291247270.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "MRNA",
                "summary": "BioNTech SE maintains a Strong Buy rating, driven by robust late-stage oncology pipeline momentum and strategic partnerships. Click for more on BNTX.",
                "category": "company",
                "datetime": 1787933252,
                "headline": "BioNTech: Reiterating Strong Buy Based On COMIRNATY Variant Expansion And More"
              },
              {
                "id": 141337777,
                "url": "https://finnhub.io/api/news?id=2475d4f0bf3820d4df188cf9c73fede62d6b646c997857e59ae8b8365a74fdba",
                "image": "https://www.chartmill.com/images/uploads/CM_Gap_Stocks_Small_free_ad767b11cf.webp",
                "source": "ChartMill",
                "related": "MRNA",
                "summary": "Stay updated with the S&P500 gap up and gap down stocks on Friday. Get a glimpse of the market's movement during today's session.",
                "category": "company",
                "datetime": 1787927701,
                "headline": "What's going on in today's session: S&P500 gap up and gap down stocks"
              },
              {
                "id": 141338793,
                "url": "https://finnhub.io/api/news?id=bd81a66323ddaec8a6c063ad55e9bab105eb706d36589a0de58b89f58003aded",
                "image": "",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "https://www.who.int/news/item/28-08-2026-second-meeting-of-the-ihr-emergency-committee-on-the-epidemic-of-ebola-bundibugyo-virus-disease-in-the-democratic-republic-of-the-congo---meeting-report",
                "category": "company",
                "datetime": 1787921002,
                "headline": "World Health Organization Director General Determined That The Ebola Epidemic In DRC Still Meets Criteria Of Public Health Emergency Of International Concern, But Not Those Of A Pandemic Emergency"
              },
              {
                "id": 141338859,
                "url": "https://finnhub.io/api/news?id=07977c7194c0c08ab025d89781c764809ea2fb3842b803570d03567cc45a0908",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/28/Moderna.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "Wall Street analysts upgraded Moderna Inc and Evolution Petroleum Corp, and raised Enbridge's price target. Check out analysts' views on MRNA stock.",
                "category": "company",
                "datetime": 1787919370,
                "headline": "This Moderna Analyst Turns Bullish; Here Are Top 3 Upgrades For Friday"
              },
              {
                "id": 141338860,
                "url": "https://finnhub.io/api/news?id=8f1ad43b451f1cb00a87c44bf5d62ab2dce04af1a82e63b8c4b309545a833237",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/28/Moderna-vaccine.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "Shares of Moderna are trading lower Friday morning after the company announced official terms for a major private debt offering.",
                "category": "company",
                "datetime": 1787908300,
                "headline": "Moderna Stock Falls Friday: What's Going On?"
              },
              {
                "id": 141338861,
                "url": "https://finnhub.io/api/news?id=c88e01c3b13b3d74b56626f21835e3e0ac39ffaad66080fbb2dec00d12daf4a5",
                "image": "",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "Argus Research  analyst John Eade   upgrades Moderna (NASDAQ:MRNA) from Hold to Buy and announces $180 price target.",
                "category": "company",
                "datetime": 1787903459,
                "headline": "Argus Research Upgrades Moderna to Buy, Announces $180 Price Target"
              },
              {
                "id": 141332095,
                "url": "https://finnhub.io/api/news?id=f563c106233d14ebb69586ee907707f00b570373de8f8e44db8bfd287e5b4889",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "MRNA",
                "summary": "Uncover the latest developments among S&P500 stocks in today's session. Stay tuned to the S&P500 index's top gainers and losers on Thursday.",
                "category": "company",
                "datetime": 1787857501,
                "headline": "What's going on in today's session: S&P500 movers"
              },
              {
                "id": 141333616,
                "url": "https://finnhub.io/api/news?id=0d52f8ed9a8c55b6fd8382288f6020e1ef954f50a94ac5eebb58f2cc3e7d4667",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/27/Benzinga-Quick-Spark.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "FDA approves updated COVID-19 vaccines for 2026-'27 season, targeting XFG variant. Limited eligibility for adults 65+ and those with high-risk conditions.",
                "category": "company",
                "datetime": 1787856373,
                "headline": "QUICK SPARK: FDA Approves Updated COVID Vaccines From Moderna, Pfizer, Novavax"
              },
              {
                "id": 141338863,
                "url": "https://finnhub.io/api/news?id=9d4155ba701f1824a32b2ea1972ac465e82bb120d4d0fb01ae1a50f3db364556",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/27/Los-Angeles--Californiaus---Circa-1990-D.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "Dolly Parton left a lasting legacy across music, TV, film and entertainment. The singer also leaves behind a lifetime of philanthropy.",
                "category": "company",
                "datetime": 1787847652,
                "headline": "Dolly Parton Life of Philanthropy May Have Kept Singer From Billionaire Status: ‘I Don’t Work for Money, Never Did’"
              },
              {
                "id": 141330387,
                "url": "https://finnhub.io/api/news?id=dfccecd78cc744f6ccfd0d8cc510992ade50a9d50a853125a543475ba9eeb032",
                "image": "https://www.chartmill.com/images/uploads/CM_Gap_Stocks_Small_free_ad767b11cf.webp",
                "source": "ChartMill",
                "related": "MRNA",
                "summary": "Looking for the S&P500 stocks that are experiencing notable gaps on Thursday? Find out which stocks are gapping up and gapping down in the S&P500 index during today's session.",
                "category": "company",
                "datetime": 1787841302,
                "headline": "Which S&P500 stocks are gapping on Thursday?"
              },
              {
                "id": 141331717,
                "url": "https://finnhub.io/api/news?id=b76b2b2c443ab9cdc5e0d7b1f80faa2c059934c65cbfad7ab85c3c4e47c4c2d8",
                "image": "https://cdn.benzinga.com/files/images/story/2025/11/06/aggregated_options_3.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "This whale alert can help traders discover the next big trading opportunities.\nWhales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.\nTraders often",
                "category": "company",
                "datetime": 1787837726,
                "headline": "10 Health Care Stocks With Whale Alerts In Today’s Session"
              },
              {
                "id": 141331674,
                "url": "https://finnhub.io/api/news?id=98fb71d56f29669c354f3f36d5711f0896d1049f66558374ce7859283953c15e",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/27/Global-Stock-Market-Rally-And-Bullish-Pe.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "Nvidia surged 9% and cybersecurity names exploded higher, yet 10 of 11 S&P 500 sectors fell as yields firmed before Jackson Hole.",
                "category": "company",
                "datetime": 1787837123,
                "headline": "Nvidia's Best Day Since April 2025, Cybersecurity Stocks Go Vertical: Stock Market Today"
              },
              {
                "id": 141331320,
                "url": "https://finnhub.io/api/news?id=cd9a23554e5459b1f2133b09f73a5b8243dfabcb1fc4885192e3eb29b1b4d2ed",
                "image": "https://image.cnbcfm.com/api/v1/image/100685508-20130419-0062-123.jpg?v=1452104328&w=1920&h=1080",
                "source": "CNBC",
                "related": "MRNA",
                "summary": "These are some of the stocks posting the largest moves midday.",
                "category": "company",
                "datetime": 1787836615,
                "headline": "Stocks making the biggest moves midday: Nvidia, Okta, Hormel, Veeva, HP, Celsius, Best Buy & more "
              },
              {
                "id": 141329708,
                "url": "https://finnhub.io/api/news?id=6eddc22315eab437a036c92d41b9413ce1649a99d12f9437bfddd25f4c2ca7de",
                "image": "https://www.chartmill.com/images/uploads/CM_Premarket_Movers_Small_free_90289f6b81.webp",
                "source": "ChartMill",
                "related": "MRNA",
                "summary": "Before the US market kicks off on Thursday, let's examine the pre-market session and unveil the notable performers among the S&P500 top gainers and losers.",
                "category": "company",
                "datetime": 1787834101,
                "headline": "These S&P500 stocks that are showing activity before the opening bell on Thursday."
              },
              {
                "id": 141331719,
                "url": "https://finnhub.io/api/news?id=997531e2ee255677892a76e5ee557d2bbc12a11a127519612b721cb6ab5be5c9",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/27/Moderna-Inc.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "Moderna announces a $2 billion convertible senior note offering to fund its oncology business growth and strategically manage debt.",
                "category": "company",
                "datetime": 1787823061,
                "headline": "Moderna Borrows $2 Billion To Expand Oncology Business"
              },
              {
                "id": 141323161,
                "url": "https://finnhub.io/api/news?id=3932a9fae53338a86b9c1755b52a37a1e4c996bff7348088d28805b5d2d417b7",
                "image": "https://www.chartmill.com/images/uploads/CM_Gap_Stocks_Small_free_ad767b11cf.webp",
                "source": "ChartMill",
                "related": "MRNA",
                "summary": "Let's have a look at the S&P500 gap up and gap down stocks in today's session.",
                "category": "company",
                "datetime": 1787754901,
                "headline": "These S&P500 stocks are gapping in today's session"
              },
              {
                "id": 141323960,
                "url": "https://finnhub.io/api/news?id=cf087cbfcf6442c6f145fa7516f2c7ae3657b296cc038e226f8f91a561b7c4f8",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/26/Stocks-Fall--Technology-Businesses-Do-No.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "Nasdaq 100 falls 0.6% as traders wait on Nvidia and hot July PCE revives September rate-hike bets. Energy leads, gold sinks 1.3% to $4,599.",
                "category": "company",
                "datetime": 1787749114,
                "headline": "Nasdaq 100 Falls as Hot PCE Inflation Stirs Rate-Hike Bets: Stock Market Today"
              },
              {
                "id": 141322666,
                "url": "https://finnhub.io/api/news?id=45404df3aec94c43e0fe19f8dea362f33c12ae578f30b5581f5f7c0ff85b82d6",
                "image": "https://www.chartmill.com/images/uploads/CM_Premarket_Movers_Small_free_90289f6b81.webp",
                "source": "ChartMill",
                "related": "MRNA",
                "summary": "Get insights into the top gainers and losers in the S&P500 index of Wednesday's pre-market session.",
                "category": "company",
                "datetime": 1787747701,
                "headline": "Top S&P500 movers in Wednesday's pre-market session"
              },
              {
                "id": 141323665,
                "url": "https://finnhub.io/api/news?id=7cae3300f222dce981ebe3f49346948333b0c20be4125230e4dec4a71cfbe720",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/26/Moderna.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "Moderna shares are trading lower Wednesday morning, pausing after a 150% surge on landmark clinical trial updates for its oncology pipeline.",
                "category": "company",
                "datetime": 1787736370,
                "headline": "Moderna Stock Dips Wednesday: What's Going On?"
              },
              {
                "id": 141323666,
                "url": "https://finnhub.io/api/news?id=639a09fd66eb61566ebe38db1bdd8d933cab4a796973b124b878d52985839f21",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/26/Lung-research.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "Sunshine Biopharma outlines K1.1 mRNA pipeline updates, advancing dual oncology therapy to target cold tumors in liver and lung cancer.",
                "category": "company",
                "datetime": 1787733069,
                "headline": "EXCLUSIVE: Sunshine Biopharma Advances Vaccine Strategy for Lung Cancer"
              },
              {
                "id": 141317763,
                "url": "https://finnhub.io/api/news?id=d9a2b22a4880b4c57a5a78e197c6c5ce8a510e121a48982bd29dab32dc155385",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "MRNA",
                "summary": "Wondering what's happening in today's session for the S&P500 index? Stay informed with the top movers within the S&P500 index on Tuesday.",
                "category": "company",
                "datetime": 1787684701,
                "headline": "Top S&P500 movers in Tuesday's session"
              },
              {
                "id": 141317450,
                "url": "https://finnhub.io/api/news?id=a9251f9283b5230d33a2e52ed6096324c868b9a20066ede8525d714353dc782a",
                "image": "https://www.chartmill.com/images/uploads/CM_Most_Active_Stocks_Small_free_fec0650b7f.webp",
                "source": "ChartMill",
                "related": "MRNA",
                "summary": "Curious about the most active S&P500 stocks in today's session? Get insights into the stocks that are leading the way in terms of trading volume and market attention.",
                "category": "company",
                "datetime": 1787681101,
                "headline": "Which S&P500 stocks are the most active on Tuesday?"
              },
              {
                "id": 141318466,
                "url": "https://finnhub.io/api/news?id=d7c7ff30c1b3e55ae13bdb52cc80cbe1f892ae0321e0f9170dd6c952b580763d",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2282220392/image_2282220392.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "MRNA",
                "summary": "Alex King from Growth Investor Pro discusses the AI cycle, semis and software.",
                "category": "company",
                "datetime": 1787679300,
                "headline": "Don't Sleep On Software"
              },
              {
                "id": 141317095,
                "url": "https://finnhub.io/api/news?id=ee8beec7883fa4ddfeb847562ae3ca72fd8deb1f4d922f4401a2f01843ed5873",
                "image": "https://www.chartmill.com/images/uploads/CM_Unusual_Volume_Small_free_b9d2e60841.webp",
                "source": "ChartMill",
                "related": "MRNA",
                "summary": "Which stocks have an unusual volume on Tuesday?",
                "category": "company",
                "datetime": 1787677200,
                "headline": "In today's session, these stocks are experiencing unusual volume."
              },
              {
                "id": 141323667,
                "url": "https://finnhub.io/api/news?id=1611ccd0d0ea9f4a09dfc97eada9d731ecf2fe6b06a4a7a293fb827103b93177",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/25/image.png?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "A key trading signal flashed for Moderna shares at a price of $151.75, after which MRNA rose over 5% to an intraday high.",
                "category": "company",
                "datetime": 1787667462,
                "headline": "Moderna Shares Rise Over 5% After Key Trading Signal"
              },
              {
                "id": 141317524,
                "url": "https://finnhub.io/api/news?id=05804c95ab58ba262bb452c5640017d019dab62d1376acde6b7416e51bb1b6fe",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/25/Golden-Bitcoin-Coin-In-Red-And-Blue-Smok.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "Wall Street clawed back Monday's AI selloff as Brent slid below $90 and 10-year yields eased from 20-month highs.",
                "category": "company",
                "datetime": 1787662856,
                "headline": "Bitcoin Tops $80,000, Oil Sinks As Navy Clears Hormuz Mines: Stock Market Today"
              },
              {
                "id": 141317152,
                "url": "https://finnhub.io/api/news?id=b0296d9ed0160108953be1b90a0b93a55834e9460c42c9978afba664f9529302",
                "image": "https://image.cnbcfm.com/api/v1/image/108231263-1764018749519-gettyimages-2247742047-DICKS_EARNS.jpeg?v=1775851544&w=1920&h=1080",
                "source": "CNBC",
                "related": "MRNA",
                "summary": "These are the stocks posting the largest moves midday.",
                "category": "company",
                "datetime": 1787659503,
                "headline": "Stocks making the biggest moves midday: Dick's Sporting Goods, Marvell, AMD, Kura Oncology & more"
              },
              {
                "id": 141316874,
                "url": "https://finnhub.io/api/news?id=741c3cd4aa2a8775149a4df1eb02c1987ad76e76490f5adcca21d397a9e67478",
                "image": "",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "Wolfe Research  analyst Alexandria Hammond   upgrades Moderna (NASDAQ:MRNA) from Underperform to Peer Perform.",
                "category": "company",
                "datetime": 1787653790,
                "headline": "Wolfe Research Upgrades Moderna to Peer Perform"
              },
              {
                "id": 141316875,
                "url": "https://finnhub.io/api/news?id=fa8a1a655519668c95ae8e211c29c5f86a9f486190381f2c9af84f64974dac66",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/25/Display-Of-Stock-Market-Quotes.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "Nasdaq: NYAX rose 13.9% on Tuesday after announcing acquisition of IPS Group Inc. for $350 million. Other big gainers include CAPR, RZLV, CRML, and MAIR.",
                "category": "company",
                "datetime": 1787652227,
                "headline": "Nayax, Immatics, Moderna, Marvell Technology And Other Big Stocks Moving Higher On Tuesday"
              },
              {
                "id": 141316572,
                "url": "https://finnhub.io/api/news?id=7fe7b223afcf23593d669003942bf277a43bdfd0531baf348b2491a66804c553",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/25/Moderna.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "Shares of Moderna are trading higher Tuesday morning, as Wall Street analysts upgrade their ratings following landmark Phase 3 oncology data.",
                "category": "company",
                "datetime": 1787649528,
                "headline": "Moderna Stock Edges Higher Tuesday: What's Happening?"
              },
              {
                "id": 141315402,
                "url": "https://finnhub.io/api/news?id=00e970b4377bb34d823acb0e17854754ef94345db03bcf36dc5610c8d1e84129",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2260474979/image_2260474979.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "MRNA",
                "summary": "US equity markets were lower this week, with weakness led by tech, Industrials, Utilities, and broader growth-oriented benchmarks. The profound structural shift in the stock market continues",
                "category": "company",
                "datetime": 1787634300,
                "headline": "ValuEngine Weekly Market Summary And Commentary"
              },
              {
                "id": 141310582,
                "url": "https://finnhub.io/api/news?id=37c77b353f564166487672d942c21d5b0eced09b4ede4b83d36496c9b06c59c3",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "MRNA",
                "summary": "Stay informed about the performance of the S&P500 index one hour before the close of the markets on Monday. Uncover the top gainers and losers in today's session for valuable insights.",
                "category": "company",
                "datetime": 1787598301,
                "headline": "Stay informed with the top movers within the S&P500 index on Monday."
              },
              {
                "id": 141310120,
                "url": "https://finnhub.io/api/news?id=b4e7862ecff49c01c686f4ff93eb405072c170ffc8e5c83fda06da0f37f4a012",
                "image": "https://www.chartmill.com/images/uploads/CM_Most_Active_Stocks_Small_free_fec0650b7f.webp",
                "source": "ChartMill",
                "related": "MRNA",
                "summary": "Stay informed about the most active S&P500 stocks in today's session as we take a closer look at what's happening on the US markets on Monday. Discover the stocks that are generating the highest trading volume and driving market activity.",
                "category": "company",
                "datetime": 1787594700,
                "headline": "What's going on in today's session: S&P500 most active stocks"
              },
              {
                "id": 141309650,
                "url": "https://finnhub.io/api/news?id=6cc3cc0b0ac81d07cd282ed985700804b5a3849ecc19d8e6a7d4d1c7a1848a2b",
                "image": "https://www.chartmill.com/images/uploads/CM_Unusual_Volume_Small_free_b9d2e60841.webp",
                "source": "ChartMill",
                "related": "MRNA",
                "summary": "Join us as we delve into today's session and uncover the stocks that are standing out with unusual volume.",
                "category": "company",
                "datetime": 1787590800,
                "headline": "The trading volume of these stocks is deviating from the norm in today's session."
              },
              {
                "id": 141308774,
                "url": "https://finnhub.io/api/news?id=0fbb69c795f1bcd179b38c2d46070486d6fbc6e32d205e66f21d16810365802c",
                "image": "https://www.chartmill.com/images/uploads/CM_Gap_Stocks_Small_free_ad767b11cf.webp",
                "source": "ChartMill",
                "related": "MRNA",
                "summary": "Curious about the market action on Monday? Dive into the US markets to explore the gap up and gap down stocks in the S&P500 index during today's session.",
                "category": "company",
                "datetime": 1787582101,
                "headline": "Monday's session: gap up and gap down stock in the S&P500 index"
              },
              {
                "id": 141310307,
                "url": "https://finnhub.io/api/news?id=48b8fa88bd71ad9473b96e5509ddc70b6ba7cf91f9ae99697aa25dfc525580c6",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/24/Tempus-AI.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "Tempus AI stock pulls back after a 20% surge as cancer data spotlights its Personalis deal, and FDA clears its pulmonary hypertension AI tool.",
                "category": "company",
                "datetime": 1787580171,
                "headline": "What’s Going On With Tempus AI Stock on Monday?"
              },
              {
                "id": 141310309,
                "url": "https://finnhub.io/api/news?id=500ff84143e098023aa003de16ff4328e912669d15deed8a52a8cb911b31ca79",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/24/Moderna.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "Shares of Moderna are trading lower Monday morning, taking a breather following a multi-day surge driven by clinical trial success.",
                "category": "company",
                "datetime": 1787565422,
                "headline": "Moderna Stock Slides Monday Following Historic Rally: What's Going On?"
              },
              {
                "id": 141302707,
                "url": "https://finnhub.io/api/news?id=351dfe7f68e2c28e4d40783769fb6f7a700d7362c99c21188d8c8b276c972f91",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Tempus AI's latest acquisition is looking like a great move.",
                "category": "company",
                "datetime": 1787488500,
                "headline": "Why Tempus AI Skyrocketed This Week"
              },
              {
                "id": 141302906,
                "url": "https://finnhub.io/api/news?id=ae24124488dfc0866911faedd21b212807a0636639fce52024ad8f6a1a687f04",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna Inc. (NASDAQ:MRNA) saw its share price more than double week-on-week to hit a new record high after reporting stellar results from the clinical trial of its melanoma therapy candidate in partnership with Merck. During the week, the stock climbed by as much as 179 percent to touch a record high of $176.66, before paring […]",
                "category": "company",
                "datetime": 1787469799,
                "headline": "Moderna (MRNA) Soars 179% as Melanoma Therapy Candidate Rewrites Growth Story"
              },
              {
                "id": 141302633,
                "url": "https://finnhub.io/api/news?id=710f3c3ca6e342bdec112e491629522821f6eb5c5c8bf1a9882b2cb278aa4676",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna's mRNA cancer vaccine breakthrough with Merck fueled a biotech rally, with the IBB near highs. Eli Lilly and Natera both show strong uptrends and possible breakouts.",
                "category": "company",
                "datetime": 1787415000,
                "headline": "2 Biotech Stocks Shaping Up for Major Breakouts"
              },
              {
                "id": 141302612,
                "url": "https://finnhub.io/api/news?id=76547bac59c31a668d5e46df733d737aea57e6553f790608f61b8ad98abfced1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Stocks fell this week as Treasury bond buybacks, oil prices, and Walmart earnings weighed on markets, while Bitcoin rallied; MarketBeat analysts cover Moderna, NVIDIA, Meta, RTX, and more.",
                "category": "company",
                "datetime": 1787400000,
                "headline": "MarketBeat Week in Review – 08/17 - 08/21"
              },
              {
                "id": 141278399,
                "url": "https://finnhub.io/api/news?id=82086bc1efdaa2e00d5b62aee111cce8180f32a2ecd47272d983de05a06c52ba",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Check out the companies making headlines this week:",
                "category": "company",
                "datetime": 1787388819,
                "headline": "Stocks making big moves this week: Bally's, Adobe, Novavax, Semtech, and STAAR Surgical"
              },
              {
                "id": 141294364,
                "url": "https://finnhub.io/api/news?id=9c7c4b6e7a4bd983931392cae935ba5ee7de9fcf2e7462339dc649abae2c0a2a",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/22/Bulls-and-Bears-1.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "Benzinga examined the prospects for many investors’ favorite stocks over the last week — here’s a look at some of our top stories.",
                "category": "company",
                "datetime": 1787385673,
                "headline": "Benzinga Bulls and Bears: Ross, Moderna, Webull"
              },
              {
                "id": 141277722,
                "url": "https://finnhub.io/api/news?id=8ae02c1a8c55194b821cc37baed5fd386d50c7034cb1a8377b58c0ef6f854110",
                "image": "",
                "source": "SeekingAlpha",
                "related": "MRNA",
                "summary": "",
                "category": "company",
                "datetime": 1787382761,
                "headline": "What Moved Markets This Week"
              },
              {
                "id": 141278394,
                "url": "https://finnhub.io/api/news?id=682b10a24c0fe3439d30e49918a13068df09a090fa5d18e903888984f117b0a8",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "ARCT stock was most recently buoyed by positive late-stage results from Merck and Moderna on their personalized mRNA cancer vaccine combined with Keytruda in high-risk melanoma patients.",
                "category": "company",
                "datetime": 1787361546,
                "headline": "ARCT Surges Over 60% Toward Best Week In Year As Moderna Cancer Win Lifts Sector — Retail Says Arcturus Getting ‘Harder To Dismiss’"
              },
              {
                "id": 141278219,
                "url": "https://finnhub.io/api/news?id=350fe7c8ba98e6524dd17860ad5c469797b726189c22f238eecd4e743634c106",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna's 130% day ran on five conditions. We screened the market for stocks like Moderna and found three names, none a biotech.",
                "category": "company",
                "datetime": 1787354045,
                "headline": "3 American Stocks Showing the Same Setup That Sent Moderna Up 177%"
              },
              {
                "id": 141278395,
                "url": "https://finnhub.io/api/news?id=b65b0ac5786dd2b0dce71b5e3f2603194a23e2f203ea0237c5a61f9d1c7c1541",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Scientists are on the cusp of fulfilling a decades-long quest: to use vaccines to teach the immune system to spot and destroy cancer cells. News that an mRNA cancer vaccine developed by Merck & Co. and Moderna Inc. kept melanoma from returning in a large, late-stage trial marks a critical next chapter for a technology beleaguered by post-pandemic political backlash and years of false starts before then. Bloomberg Opinion Columnist Lisa Jarvis writes \"Moderna and Merck's Cancer Vaccine Is a Marvel.\"",
                "category": "company",
                "datetime": 1787353141,
                "headline": "Moderna, Merck Cancer Vax Gives Hope"
              },
              {
                "id": 141278401,
                "url": "https://finnhub.io/api/news?id=c0c318a6613f04793c35da84472cfac03ee0702d00d8d6e7de919298c14b9dbd",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "The stock has gained over 20% in the past five days, marking its best week since early July.",
                "category": "company",
                "datetime": 1787350771,
                "headline": "SLS Stock Clocks Three Straight Weeks Of Gains On Cancer Vaccine Spillover, REGAL Trial Data Anticipation"
              },
              {
                "id": 141273220,
                "url": "https://finnhub.io/api/news?id=8140b108801b2d518124ff23a413996f21d5e457e117de7876aca0b97880d25a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna shares rise to close out a week of wild swings. Crypto stocks also extend their recent rally.",
                "category": "company",
                "datetime": 1787347080,
                "headline": "Moderna, Robinhood, Marvell, Tesla, SpaceX, and More Stocks That Explain Today’s Market"
              },
              {
                "id": 141278402,
                "url": "https://finnhub.io/api/news?id=c007d7ae352542bcd167be2873b9aa69ef81d0951a36bac9af3d7ff47e073bfd",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "It's been a good week for healthcare, with one stock's dramatic gains driving the sector higher.  Moderna stock saw its best weekly performance ever, rising over 140%.  The stock surged after the pharmaceutical giant announced promising results out of trials for its cancer vaccine.",
                "category": "company",
                "datetime": 1787342256,
                "headline": "Thank Moderna for the Healthcare Sector’s Standout Week"
              },
              {
                "id": 141278397,
                "url": "https://finnhub.io/api/news?id=38dd0d7e7c6eb6285ae70cc42b7302f86dda418041d32af3c76017a0115b343f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "The success of Moderna and Merck’s intismeran autogene doesn’t guarantee smooth sailing for other mRNA vaccine developers",
                "category": "company",
                "datetime": 1787342040,
                "headline": "Can mRNA Cure Cancer? Inside the Pipeline Risks for Biotech’s Biggest Players"
              },
              {
                "id": 141278404,
                "url": "https://finnhub.io/api/news?id=788d907d139c172024a8da133d9395afb9596075f23fe3075ee239879373a942",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Investing.com -- A historic single-day move in biotech dominated the week, while a Treasury liquidity announcement impacted crypto and metals. Two well-known consumer names went in opposite directions on earnings.",
                "category": "company",
                "datetime": 1787340370,
                "headline": "Investing.com’s stocks of the week"
              },
              {
                "id": 141278398,
                "url": "https://finnhub.io/api/news?id=627be7edc9f9bb24e26e8db1d3eb01a347be9c47be9302779448c5d5f59825cc",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna's cancer treatment could treat more than just Melanoma, though the stock's momentum is already stalling. Should you still buy the dip?",
                "category": "company",
                "datetime": 1787340255,
                "headline": "Moderna Just Doubled on a Massive Cancer Breakthrough. Here’s Why MRNA Stock Isn’t a Buy Yet."
              },
              {
                "id": 141272165,
                "url": "https://finnhub.io/api/news?id=60f0df094fa5500e24b2d1e119b1523344538360e16ca95eb13e8cd7ffae6ba6",
                "image": "https://www.chartmill.com/images/uploads/CM_Top_Movers_Small_free_2b4ff2fc22.webp",
                "source": "ChartMill",
                "related": "MRNA",
                "summary": "Wondering what's happening in today's session for the S&P500 index? Stay informed with the top movers within the S&P500 index on Friday.",
                "category": "company",
                "datetime": 1787339101,
                "headline": "Explore the top gainers and losers within the S&P500 index in today's session."
              },
              {
                "id": 141281302,
                "url": "https://finnhub.io/api/news?id=6be02ab1951d7f5d67c8ff2a149e3e913541c81dd4fadeef9117066b76b98239",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Yesterday’s unusual options activity revealed a massive 20,000-contract bull call spread on Pacific Gas & Electric (PCG). The low-risk, high-reward October trade risks $1.2 million for a potential $8.8 million payout, eyeing potential California wildfire reforms.",
                "category": "company",
                "datetime": 1787337002,
                "headline": "Unusual Options Activity Shows 1 Institutional Trader Is Making a Big Bet on PG&E Stock"
              },
              {
                "id": 141271515,
                "url": "https://finnhub.io/api/news?id=c44337b50efe0da34e7f47d53a781801f081fdbdc9b1b80bf495179c51b14ae9",
                "image": "https://www.chartmill.com/images/uploads/CM_Most_Active_Stocks_Small_free_fec0650b7f.webp",
                "source": "ChartMill",
                "related": "MRNA",
                "summary": "Stay informed about the most active stocks in the S&P500 index on Friday's session. Discover the stocks that are generating the highest trading volume and driving market activity.",
                "category": "company",
                "datetime": 1787335501,
                "headline": "Which S&P500 stocks are the most active on Friday?"
              },
              {
                "id": 141273836,
                "url": "https://finnhub.io/api/news?id=54587dab906d987614824cfab5a6a06e39d1174079f537b68a0616ac939e493d",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/21/New-York--Ny--Usa---11-05-2024-Wall-Stre.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "Retail investors talked up 5 hot stocks during the week (Aug. 17 to Aug. 21) on X and Reddit's r/WallStreetBets: MRNA, WMT, MSTR, AVGO, SPCX",
                "category": "company",
                "datetime": 1787335233,
                "headline": "MRNA, SPCX, MSTR and More: 5 Stocks Investors Couldn't Stop Buzzing About This Week"
              },
              {
                "id": 141271514,
                "url": "https://finnhub.io/api/news?id=b62b5a1624ff2850df9325358f0ff808fb927cb74bae610bd929dc9712420e38",
                "image": "https://www.chartmill.com/images/uploads/CM_Most_Active_Stocks_Small_free_fec0650b7f.webp",
                "source": "ChartMill",
                "related": "MRNA",
                "summary": "These stocks are making the most noise in today's session. Stay tuned for the latest updates!",
                "category": "company",
                "datetime": 1787335200,
                "headline": "Friday's session: most active stocks"
              },
              {
                "id": 141271041,
                "url": "https://finnhub.io/api/news?id=9231dfaaa078db6b0e4386a813af19bafd76733ef919ab02892aacbfdb3f019c",
                "image": "https://www.chartmill.com/images/uploads/CM_Unusual_Volume_Small_free_b9d2e60841.webp",
                "source": "ChartMill",
                "related": "MRNA",
                "summary": "Let's take a closer look at the S&P500 stocks with an unusual volume in today's session on Friday. Stay informed about the market activity below.",
                "category": "company",
                "datetime": 1787331900,
                "headline": "Which S&P500 stocks have an unusual volume on Friday?"
              },
              {
                "id": 141274436,
                "url": "https://finnhub.io/api/news?id=284f8db205b3026a9f7fd1a7d5e062ee29303414d25d0d0a5189774496cd7747",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/21/Us-Treasury-Secretary--Scott-Bessent-Wal.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "Moderna's biggest one-day rally ever, Bitcoin's best week since February 2023, and Walmart's 9% slide capped a volatile week driven by Bessent's bond rescue.",
                "category": "company",
                "datetime": 1787328101,
                "headline": "Bessent's Bond Band-Aid, Bitcoin's Best Week Since 2023: This Week on Wall Street"
              },
              {
                "id": 141281303,
                "url": "https://finnhub.io/api/news?id=e572ad963a107439a57827d0ebbc1fcc3b86c5b9d38cc612ce1d602c423f8172",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna stock could catch the eye of investors looking for the next big AI play, Revere Asset Management's Don Vandenbord says.",
                "category": "company",
                "datetime": 1787327370,
                "headline": "Moderna Stock Is Just The Start: Why AI-Focused Money Might Flow Into Biotech"
              },
              {
                "id": 141278409,
                "url": "https://finnhub.io/api/news?id=0693331366acda03bfcd5a167bea14df1950cd4e7abffeb35a05ea64ba6e2429",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "The market rally flashed some bearish signals. Moderna skyrocketed on a cancer vaccine while gold and bitcoin jumped. Walmart dived.",
                "category": "company",
                "datetime": 1787326311,
                "headline": "Stock Market Rally Buckles; Moderna, Gold, Bitcoin Surge While Walmart Tumbles: Weekly Review"
              },
              {
                "id": 141278410,
                "url": "https://finnhub.io/api/news?id=11965b7623d404e18587fc0c0bbc876ea040961b86425f3109227d7743d0a687",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Moderna has now swung violently in both directions for three straight sessions on the same unchanged clinical news, and the options chain hints at why this whipsaw is far from over.",
                "category": "company",
                "datetime": 1787324767,
                "headline": "Moderna Rallies 8%, BioNTech Climbs 4% as the mRNA Trade Whipsaws for a Third Session"
              },
              {
                "id": 141278075,
                "url": "https://finnhub.io/api/news?id=ffe6cb0273861f20770610b9b0624ed6673a06dae9f7dc14902717e568c95c6d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "JPMorgan layoffs hit highest since 2015, Amazon expands drone delivery, Chinese tech IPOs outshine U.S. rivals, and more news to start your day.",
                "category": "company",
                "datetime": 1787317800,
                "headline": "Bonds, Cryptos, Moderna Play Havoc With Markets. 2 Reasons for More Chaos."
              },
              {
                "id": 141273478,
                "url": "https://finnhub.io/api/news?id=efefe9bbbeab1654bc7f7bef800af2a084503a6408f913658e7b1ab0e71a833a",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/21/Moderna-Logo-With-Vials-And-Syringe.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "Moderna stock soars on recent Phase 3 trial results. A look back at the company's IPO and the stock's ups and downs since.",
                "category": "company",
                "datetime": 1787317764,
                "headline": "If You Invested $1,000 In Moderna Stock at IPO, Here's How Much You'd Have Now"
              },
              {
                "id": 141278039,
                "url": "https://finnhub.io/api/news?id=e68f6a3a542ae07d07afd9a4c2837484ae1d71fbd4f4419f681e7005fbb1abf7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "The  exchange-traded fund, home to some large pharma companies and many smaller biotechs, has risen over 6% this week.  The main catalyst was  Moderna  and  Merck  announcement of  successful trial data for a melanoma vaccine that reduces the risk patients will experience recurrence.  “The read-through [from Merck and Moderna] to the others is probably indicative of a broader tailwind of pharma taking some strong actions to improve their long-term growth profiles,” says Cantor Fitzgerald analyst Carter Gould.",
                "category": "company",
                "datetime": 1787317680,
                "headline": "Pharma Stocks Have Rallied. 2 Stocks to Avoid—and 2 to Buy."
              },
              {
                "id": 141271561,
                "url": "https://finnhub.io/api/news?id=389571a61c544b9ab404b5772ede85abe1dc3388aa5cab3e96ab9099759802b8",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/21/Bitcoin-Hits-Record-109-000-Ahead-Of-Tru.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "Stocks steadied Friday as bond yields stabilized, Robinhood and Coinbase surged on CLARITY Act optimism, and gold hit a three-month high.",
                "category": "company",
                "datetime": 1787317412,
                "headline": "Bitcoin Jumps Above $77,000, Gold Hits 3-Month Highs: Stock Market Today"
              },
              {
                "id": 141278313,
                "url": "https://finnhub.io/api/news?id=6bcc8911359f6782aad16e9be6acf31e86bcbc3c25bde6ccd190e36849300d35",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "MRNA",
                "summary": "Futures rose after the Nasdaq closed below its Aug. 4 low, a bearish market signal. Bitcoin momentum continues.",
                "category": "company",
                "datetime": 1787317053,
                "headline": "Dow Jones Futures Rise After Bearish Market Signal; Bitcoin Keeps Surging"
              },
              {
                "id": 141271592,
                "url": "https://finnhub.io/api/news?id=4ccb9bd36bb8a00713c20c640e27a331b45cc37108e9197b705e906827562b67",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/21/Stock-And-Buyback-Write-On-Sticky-Notes-.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "Arbutus Biopharma (ABUS) stock rises after announcing a $230M stock buyback via a modified Dutch auction. Get the offer details.",
                "category": "company",
                "datetime": 1787315770,
                "headline": "Why Is Arbutus Biopharma Stock Gaining Friday?"
              },
              {
                "id": 141271055,
                "url": "https://finnhub.io/api/news?id=5f4598b0d6ba255f594f708ce90e97cacf249bf22caddb167020847d33773921",
                "image": "https://image.cnbcfm.com/api/v1/image/107245920-1684930328222-gettyimages-1492705069-wm3_0004_2mhohkdz.jpeg?v=1787329951&w=1920&h=1080",
                "source": "CNBC",
                "related": "MRNA",
                "summary": "These are some of the stocks posting the largest moves midday.",
                "category": "company",
                "datetime": 1787314912,
                "headline": "Stocks making the biggest moves midday: Moderna, Robinhood, BJ's Wholesale, Coinbase & more"
              },
              {
                "id": 141274440,
                "url": "https://finnhub.io/api/news?id=52c264b602d4566df3a5af9cb729881c04c336b7bef807263347ed2c3351629a",
                "image": "",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "JP Morgan  analyst Jessica Fye   maintains Moderna (NASDAQ:MRNA) with a Underweight and raises the price target from $40 to $77.",
                "category": "company",
                "datetime": 1787314078,
                "headline": "JP Morgan Maintains Underweight on Moderna, Raises Price Target to $77"
              },
              {
                "id": 141271225,
                "url": "https://finnhub.io/api/news?id=d2fb3acec40eb143a8d943119da90d9092dbd8876d9dabab946f1654d13fbc8c",
                "image": "https://image.cnbcfm.com/api/v1/image/108352798-6ED4-LateMorning-082126.jpg?v=1787327747&w=1920&h=1080",
                "source": "CNBC",
                "related": "MRNA",
                "summary": "CNBC brings you fast, accurate, and actionable business news and market updates.",
                "category": "company",
                "datetime": 1787313695,
                "headline": "The Late Morning Rundown: August 21, 2026"
              },
              {
                "id": 141270540,
                "url": "https://finnhub.io/api/news?id=116c11c87c38da79036c16efcd11562a853d9083eec117f66078dbf626d0cc71",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2229006239/image_2229006239.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "MRNA",
                "summary": "SCHD beat bearish macro trends as ABT, MRK & AMGN surged. Learn why dividend growth makes waiting costly—and what to do now.",
                "category": "company",
                "datetime": 1787311688,
                "headline": "SCHD: We Were Horribly Wrong"
              },
              {
                "id": 141274441,
                "url": "https://finnhub.io/api/news?id=75bb137aea44f47bfd17ffe54415ef6589f9d8609752bb4b94002ea857dfd2b0",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/21/Kyiv--Ukraine---December-01--2020-Modern.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "Moderna's Phase 3 cancer vaccine breakthrough could mark a turning point as the biotech company looks to move beyond its COVID-era identity.",
                "category": "company",
                "datetime": 1787309089,
                "headline": "COVID-19 Made Moderna Famous: Cancer Could Define Its Future"
              },
              {
                "id": 141270389,
                "url": "https://finnhub.io/api/news?id=56e29be6ca6e87d3fa59efd1ea850109ec37dead66406b6fb56e45c0e983fa3b",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/21/Display-Of-Stock-Market-Quotes.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "Dow Jones index gained around 350 points on Friday. MARA Holdings Inc (NASDAQ: MARA) rose sharply, while Bitcoin (CRYPTO: BTC) also traded higher. Other stocks recording gains include Evolution Metals (NASDAQ: EMAT), TRON (NASDAQ: TRON), Bakkt (NYSE: BKKT), Rezolute (NASDAQ: RZLT), Gemini Space Station (NASDAQ: GEMI), Robinhood Markets (NASDAQ: HOOD), Strive (NASDAQ: ASST), Moderna (NASDAQ: MRNA), Coinbase Global (NASDAQ: COIN), Bitdeer Technologies (NASDAQ: BTDR), and Circle Internet Group (NYSE: CRCL).",
                "category": "company",
                "datetime": 1787307510,
                "headline": "MARA Holdings, Coinbase Global, Ternium And Other Big Stocks Moving Higher On Friday"
              },
              {
                "id": 141268893,
                "url": "https://finnhub.io/api/news?id=6ce35ac37bb20f3f0877546c5a59b6279b06bd0bba9d04f6c33f383c18cea0c3",
                "image": "https://www.chartmill.com/images/uploads/THUMBNAILS_CHARTMILL_1000_528_2026_08_21T105840_288_f7f25158ae.webp",
                "source": "ChartMill",
                "related": "MRNA",
                "summary": "US stocks closed sharply lower on Thursday, August 20, 2026, as Walmart's downbeat outlook wiped nearly 10% off the shares, President Trump threatened Iran with the harshest sanctions package ever from Monday, and long-dated Treasury yields ticked higher again. John Deere's Q3 beat and a bitcoin surge past $70,000 offered the only real bright spots.",
                "category": "company",
                "datetime": 1787301595,
                "headline": "Walmart's Guide-Down Sinks the Dow as Trump Readies an \"Economic D-Day\" for Iran"
              },
              {
                "id": 141263200,
                "url": "https://finnhub.io/api/news?id=de80fd99b19d51b1c063dd5d4eb7830387e2c641e2ad3bda312e7bbd5d6af86f",
                "image": "https://www.chartmill.com/images/uploads/CM_Most_Active_Stocks_Small_free_fec0650b7f.webp",
                "source": "ChartMill",
                "related": "MRNA",
                "summary": "Let's have a look at what is happening on the US markets on Thursday. Below you can find the most active S&P500 stocks in today's session.",
                "category": "company",
                "datetime": 1787249101,
                "headline": "Looking for the most active stocks in the S&P500 index on Thursday?"
              },
              {
                "id": 141263199,
                "url": "https://finnhub.io/api/news?id=c9bf85700aaf607389079bd2ea55ee977d782ea9d2036f135b78b20d51a2dd46",
                "image": "https://www.chartmill.com/images/uploads/CM_Most_Active_Stocks_Small_free_fec0650b7f.webp",
                "source": "ChartMill",
                "related": "MRNA",
                "summary": "Thursday's session is buzzing with activity. Check out the stocks that are attracting the most attention and driving market activity!",
                "category": "company",
                "datetime": 1787248800,
                "headline": "Thursday's session: most active stocks"
              },
              {
                "id": 141262580,
                "url": "https://finnhub.io/api/news?id=7331752cc419ad64f9aa6e49025d689af93df70838588261a963b920c9235e73",
                "image": "https://www.chartmill.com/images/uploads/CM_Unusual_Volume_Small_free_b9d2e60841.webp",
                "source": "ChartMill",
                "related": "MRNA",
                "summary": "Let's have a look at the S&P500 stocks with an unusual volume in today's session.",
                "category": "company",
                "datetime": 1787245500,
                "headline": "Curious about which S&P500 stocks are generating unusual volume on Thursday? Find out below."
              },
              {
                "id": 141271233,
                "url": "https://finnhub.io/api/news?id=c8ad4054f6b93dc494f91f0d17333b275d49576ee3e3d66126158647f3689e2a",
                "image": "https://image.cnbcfm.com/api/v1/image/108352412-17872578651787257862-47886674828-1080pnbcnews.jpg?v=1787257864&w=1920&h=1080",
                "source": "CNBC",
                "related": "MRNA",
                "summary": "CNBC's Kristina Partsinevelos joins 'Closing Bell' to discuss the stocks she's watching.",
                "category": "company",
                "datetime": 1787243677,
                "headline": "Moderna shares pull back"
              },
              {
                "id": 141263370,
                "url": "https://finnhub.io/api/news?id=25d499e46aeb182c99566a316b221ca050055e16c61d83cc8d1dd14cfb670a63",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2194222148/image_2194222148.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "MRNA",
                "summary": "Buy XBI now: SPDR S&P Biotech ETF up 34% since March on M&A and trial catalysts.",
                "category": "company",
                "datetime": 1787235957,
                "headline": "XBI: Biotech's Breakthrough Moment Happend This Week (Upgrade)"
              },
              {
                "id": 141266096,
                "url": "https://finnhub.io/api/news?id=12671ac5e83779828cb0ce8fe50860cdd8b73b4b7f4a086d45b45f6ef60a66ba",
                "image": "",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "Goldman Sachs  analyst Salveen Richter   maintains Moderna (NASDAQ:MRNA) with a Neutral and raises the price target from $67 to $120.",
                "category": "company",
                "datetime": 1787234272,
                "headline": "Goldman Sachs Maintains Neutral on Moderna, Raises Price Target to $120"
              },
              {
                "id": 141263028,
                "url": "https://finnhub.io/api/news?id=a416f35b58578fb8808f2f0ce869185a8f7a63179d21aedf5e629b09dbf3483f",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1386962515/image_1386962515.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "MRNA",
                "summary": "Virtus Biotech ETF (BBP) gets a buy rating: equal-weight, quarterly rebalanced exposure to FDA-approved biotechs, deal activity & GLP-1 tailwinds.",
                "category": "company",
                "datetime": 1787234055,
                "headline": "BBP: The Biotech ETF That Filters For FDA-Approved Drugs"
              },
              {
                "id": 141264444,
                "url": "https://finnhub.io/api/news?id=2aadb4debe16219f9578212ef6073d8a48dd765776e660a254ec7af57c751400",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/20/Benzinga-Quick-Spark.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "Moderna closed up 176.97% on first-ever Phase 3 win for an mRNA cancer vaccine, then gave back as much as a quarter of it the next day.",
                "category": "company",
                "datetime": 1787233734,
                "headline": "QUICK SPARK: Moderna Stock Drops 25%, Eyes Worst Day in Company's History"
              },
              {
                "id": 141263663,
                "url": "https://finnhub.io/api/news?id=b9ae4613669603267f6c067feff6ec8de6891cf3e48fff5457fb7f1907a8f1c0",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/20/3D-Illustration-Depicting-Cancer-Cells-I.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "Iovance Biotherapeutics stock hits a 52-week high as investors weigh Moderna-Merck cancer data, Amtagvi sales and analyst price target hikes.",
                "category": "company",
                "datetime": 1787231698,
                "headline": "Why Iovance Biotherapeutics Stock Hit 52-Week High"
              },
              {
                "id": 141263630,
                "url": "https://finnhub.io/api/news?id=64f0887169335f9343a469b7b2728f518e8c07b180ed492548037ab2cd1a62c2",
                "image": "https://cdn.benzinga.com/files/images/story/2025/11/06/movers_3.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "Gainers\n\nIndaptus Therapeutics (NASDAQ:INDP) shares moved upwards by 34.0% to $1.26 during Thursday's regular session. The company's market cap stands at $125.2 million. \nBioVie (NASDAQ:BIVI) stock rose 30.85%",
                "category": "company",
                "datetime": 1787231181,
                "headline": "12 Health Care Stocks Moving In Thursday's Intraday Session"
              },
              {
                "id": 141262651,
                "url": "https://finnhub.io/api/news?id=c9d78559897470f3052b28bb595ce9dd1d065a7a355911da0c46f7898b000346",
                "image": "https://image.cnbcfm.com/api/v1/image/108348727-1786564871180-gettyimages-2289554840-golba-dailylif260803_npNAH.jpeg?v=1786564923&w=1920&h=1080",
                "source": "CNBC",
                "related": "MRNA",
                "summary": "These are some of the stocks posting the largest moves midday.",
                "category": "company",
                "datetime": 1787231148,
                "headline": "Stocks making the biggest moves midday: Walmart, Deere, CrowdStrike, Moderna & more "
              },
              {
                "id": 141262763,
                "url": "https://finnhub.io/api/news?id=3f3a28f79218cb81b53764c2f6a3e497a8c47216dad56246efc6c5c12b4bd996",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/20/Us-Treasury-Secretary--Scott-Bessent-Wal.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "Long-end Treasury yields snapped back toward 20-month highs; Walmart posted its worst session in four years.",
                "category": "company",
                "datetime": 1787230977,
                "headline": "Bessent's Bond Rescue Fizzles, Walmart Craters 9%: Stock Market Today"
              },
              {
                "id": 141263641,
                "url": "https://finnhub.io/api/news?id=5d1c3279b1b545b5059b047cc554eb412cfac84ee11ad4eb6127fe31e9b9d83b",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/20/Close-up-View-Of-An-Abstract-Molecular-S.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "The iShares Biotechnology ETF is trading at new highs and 18 out of its top 20 constituents are green for the year.",
                "category": "company",
                "datetime": 1787227385,
                "headline": "Biotech Is Booming, But These 2 Stocks Missed the Memo"
              },
              {
                "id": 141266102,
                "url": "https://finnhub.io/api/news?id=3def7c9ef242d275477eb9ffae4c5db7607841cd95abfe0c1e1d5d2018a499b8",
                "image": "",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "UBS  analyst Michael Yee   maintains Moderna (NASDAQ:MRNA) with a Neutral and raises the price target from $50 to $150.",
                "category": "company",
                "datetime": 1787226902,
                "headline": "UBS Maintains Neutral on Moderna, Raises Price Target to $150"
              },
              {
                "id": 141264450,
                "url": "https://finnhub.io/api/news?id=81953aae4b3cce9c57f1f27ba6c6ee7d0fe9fd5f5db41ca84814fbaf25814bd8",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/20/Moderna-Inc.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "William Blair upgraded Moderna to Outperform, citing higher intismeran approval odds and a multibillion-dollar oncology sales opportunity.",
                "category": "company",
                "datetime": 1787223773,
                "headline": "Moderna's Intismeran Close to Keytruda Style Oncology Opportunity: Analyst"
              },
              {
                "id": 141264452,
                "url": "https://finnhub.io/api/news?id=8799c7b1be844f7bdd70b8d12c7c28fc8dcbbf1604870732897f7c765a3b0b8b",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/20/Gut-Microbiome-Linked-Colon-Cancer.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "Pharma Bro Martin Shkreli admits shorting Moderna at $80 just weeks before a landmark cancer vaccine win sparked a 177% stock explosion.",
                "category": "company",
                "datetime": 1787215976,
                "headline": "Pharma Bro Admits 'Playing Around' With MRNA Short At $80 Before it Exploded 177% Following Cancer Vax Trials— ‘I Bet You a Bunch of People Got Fired’"
              },
              {
                "id": 141261780,
                "url": "https://finnhub.io/api/news?id=bdf52e47b57a45524ab51963ebe64f43e347599af34cade8a165280971f79d8d",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/20/New-York--Ny--Usa---11-05-2024-Wall-Stre.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "Editor’s note: The ETFs data was updated and economic data was added\n\n\n\nU.S. stock futures were lower on Thursday, as the Dow Jones, S&P 500 and Nasdaq 100 indices fell, following Wednesday’s higher",
                "category": "company",
                "datetime": 1787214974,
                "headline": "Stock Market Today: Dow Jones, S&P 500, Nasdaq 100 Futures Fall as Trump Launches ‘Operation Economic Fury’ on Iran— BULL, WMT, MRK Stock in Focus (UPDATED)"
              },
              {
                "id": 141264455,
                "url": "https://finnhub.io/api/news?id=a927e529fa3d828492e6c559d766861b09c7978686f9c68f42c09ae836f8fede",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/20/Tempus-AI.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "Tempus AI (TEM) trades higher after positive Phase 3 mRNA cancer trial results spotlight its $1.5B acquisition of Personalis.",
                "category": "company",
                "datetime": 1787214954,
                "headline": "Why Is Tempus AI Stock Gaining Thursday?"
              },
              {
                "id": 141261710,
                "url": "https://finnhub.io/api/news?id=6eabbfd293f00b11fa7b0d65344a4f503d89c94b82d3fbd4985dd1bdd77570cb",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/20/Okta-Sign-Building-In-Soma-District--Okt.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "MRNA",
                "summary": "Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.",
                "category": "company",
                "datetime": 1787213997,
                "headline": "Okta To Rally More Than 20%? Here Are 10 Top Analyst Forecasts For Thursday"
              }
            ],
            "data_source": "finnhub_news_keyword_model",
            "article_count": 8,
            "negative_hits": 0,
            "positive_hits": 2,
            "recomputed_at_score": true,
            "sentiment_score_raw": 0.6,
            "source_article_count": 239,
            "discarded_article_count": 214
          },
          "sentimentPoints": 4
        }
      },
      "技術信號": {
        "max": 30,
        "raw": 15.9,
        "grade": "較差",
        "items": {
          "bbPoints": 3,
          "adxPoints": 3,
          "sarPoints": 1.2000000000000002,
          "vcpPoints": 1,
          "macdPoints": 2.4,
          "vcpPayload": {
            "vcp_pass": false,
            "vcp_score": 1,
            "vcp_reason": "跌縮量(近10日5日)；站上MA50；Ready=N；Confirm=N",
            "vcp_metrics": {
              "up_days": 3,
              "vol_ref": 24509713.333333332,
              "down_days": 6,
              "vcp_ready": false,
              "above_ma50": true,
              "avg_vol_10": 16686890,
              "avg_vol_20": 33845240,
              "avg_vol_30": 24509713.333333332,
              "range_pct_10": 0.18083621587830795,
              "range_pct_20": 0.8046120719594361,
              "range_pct_30": 0.8612905466416615,
              "up_expand_ok": false,
              "lookback_used": 59,
              "near_20d_high": false,
              "contraction_ok": false,
              "down_shrink_ok": true,
              "up_expand_days": 1,
              "breakout_20d_ok": false,
              "vol_ratio_10_30": 0.6808276283389144,
              "dist_to_20d_high": 0.18504471866862898,
              "down_shrink_days": 5,
              "breakout_level_20d": 176.66,
              "vcp_breakout_confirm": false,
              "contraction_ratio_10_30": 0.2099595967741935
            },
            "vcp_name_en": "Volatility Contraction Pattern",
            "vcp_name_zh": "波動收縮形態",
            "vol_contraction": false
          },
          "kdjAdxPoints": 0.5,
          "rsiKdjPoints": 2.4,
          "volumeWeight": 2,
          "maCrossPoints": 1.6,
          "shortRsiPoints": 0,
          "shortMacdPoints": 0.4,
          "volConfirmPoints": 0,
          "volumePointsTechnical": 0.4
        }
      },
      "風險管理": {
        "max": 10,
        "grade": "較差",
        "items": {
          "position": {
            "score": 1.1,
            "details": {
              "atrPct": 8.33361116899354,
              "turnoverUsdM": 2212.88728575,
              "liquidityPoints": 0.8,
              "volatilityPoints": 0.3
            }
          },
          "rrPoints": 1.4,
          "stopLevels": {
            "symbol": "US.MRNA",
            "rr_range": "1:1.0-1:2.5",
            "risk_profile": "中等",
            "stop_loss_price": 119.9742,
            "strength_details": {
              "ma_score": 1.5,
              "atr_score": 1,
              "rsi_score": 1,
              "macd_score": 1.5,
              "volume_score": 1
            },
            "market_adjustment": 1,
            "risk_reward_ratio": 1,
            "stop_loss_percent": 16.7,
            "take_profit_price": 159.6473,
            "target_multiplier": 1.6,
            "technical_strength": 1.22,
            "take_profit_percent": 10.9
          },
          "positionPoints": 1.1,
          "stopLossPoints": 0.6,
          "diversification": {
            "score": 2,
            "details": {
              "method": "sector concentration proxy; no portfolio holdings used",
              "sector": "Health Care",
              "concentratedSectorPenalty": 0
            }
          },
          "riskRewardRatio": 1.2,
          "stopLossPercent": 15,
          "diversificationPoints": 2
        }
      }
    }
  },
  "modelVersion": "cursor_18_27_news_v2_160",
  "providerErrors": [
    {
      "code": "VIX_MISSING",
      "symbol": "US.MRNA",
      "message": "VIX market context is required for market environment scoring",
      "missing": [
        "VIX"
      ],
      "provider": "scoring"
    }
  ],
  "rankingScoreMax": 160,
  "dataCompleteness": {
    "complete": false,
    "missingFields": [
      "VIX"
    ],
    "optionalInputs": [
      "institutionalData"
    ],
    "requiredInputs": [
      "fundamentals",
      "marketContext.VIX",
      "marketContext.SPY",
      "marketContext.QQQ",
      "catalystData",
      "sentimentData",
      "ATR",
      "sector"
    ],
    "optionalInputWarnings": []
  },
  "technicalIndicators": {
    "adx": 92.86,
    "atr": {
      "atr": 11.9979,
      "rule": "ATR / current price; lower volatility scores higher",
      "score": 2,
      "atr_pct": 8.33
    },
    "cci": {
      "rule": "Cursor_18.24 CCI bands",
      "level": "平衡",
      "score": 6,
      "value": 34.36
    },
    "cmf": {
      "rule": "Cursor_18.24 CMF bands",
      "level": "資金流入",
      "score": 8,
      "value": 0.2816
    },
    "kdj": {
      "d": 42.69,
      "j": 30.37,
      "k": 38.58,
      "rule": "Cursor_18.24 K/D cross",
      "score": 0,
      "signal": "死叉"
    },
    "mfi": {
      "rule": "Cursor_18.24 MFI bands",
      "level": "弱流入",
      "score": 4,
      "value": 45.22
    },
    "obv": {
      "rule": "Cursor_18.24 recent_slope vs previous_slope",
      "score": 6,
      "trend": "有流入",
      "value": 186113575,
      "recentSlope": 386717.5,
      "previousSlope": 13155830
    },
    "rsi": 49.36,
    "sar": {
      "rule": "Cursor_18.24 Parabolic SAR",
      "score": 4,
      "trend": "下降",
      "value": 169.3897,
      "position": "SAR喺價上",
      "distancePct": 17.66,
      "previousTrend": "下降"
    },
    "ma50": 91.0366,
    "macd": {
      "macd": 16.499610391046787,
      "trend": "中性偏多",
      "signal": 19.08398092791225,
      "histogram": -2.584370536865464
    },
    "vwap": {
      "rule": "Cursor_18.24 VWAP 20D consecutive close",
      "score": 2,
      "value": 145.6917,
      "position": "<VWAP",
      "consecutiveAbove": 0
    },
    "volume": {
      "rule": "Cursor_18.24 volume ratio",
      "level": "空升",
      "ratio": 0.45,
      "score": 2,
      "avgVolume": 34205779,
      "currentVolume": 15370475
    },
    "derived": {
      "ma20": 133.404,
      "ma50": 91.0366,
      "prevClose": 136.62,
      "avgVolume10": 15724618,
      "avgVolume20": 34205779,
      "changePercent": 5.38,
      "avgVolumeForScore": 34205779
    },
    "ma_cross": {
      "ma20": 133.404,
      "ma50": 91.0366,
      "rule": "Cursor_18.24 MA20/MA50 cross",
      "cross": "多頭",
      "score": 4,
      "prevMa20": 129.388,
      "prevMa50": 89.6072,
      "spreadPct": 46.54,
      "isVolumeBreakout": false
    },
    "bollinger": {
      "lower": 72.0175,
      "upper": 194.7905,
      "position": "上半部"
    },
    "rsi_short": 35.48,
    "macd_short": {
      "macd": 0,
      "trend": "中性",
      "signal": 0,
      "histogram": 0
    },
    "volume_ratio": {
      "ratio": 0.45
    }
  }
}

{
  "close": 143.97,
  "volume": 15370475,
  "changePercent": 5.38
}